Conditions:   Colorectal Neoplasms;   Digestive System Diseases;   Colonic Diseases;   Colorectal Cancer
Intervention:  
Sponsors:   Exact Sciences Corporation;   Exact Sciences Corporation
Recruiting - verified May 2012

Condition:   Multiple Myeloma
Interventions:   Drug: Placebo;   Drug: Dexamethasone;   Drug: Bortezomib;   Biological: Tabalumab
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Not yet recruiting - verified May 2012

Condition:   Breast Cancer
Intervention:  
Sponsors:   Genentech;   Genentech;   23andMe, Inc.
Recruiting - verified May 2012

Conditions:   Acute Lymphocytic Leukemia;   Acute Myelogenous Leukemia;   Burkitt's Lymphoma;   Follicular Lymphoma;   Hodgkin Lymphoma;   Mantle Cell Lymphoma
Interventions:   Drug: Biological/Vaccine: Haploidentical BMT;   Drug: Double Cord Blood Transplantation
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network
Not yet recruiting - verified May 2012

Condition:   Mantle Cell Lymphoma
Intervention:   Drug: Ibrutinib
Sponsors:   Janssen Research & Development, LLC;   Janssen Research & Development, LLC
Not yet recruiting - verified May 2012

Condition:   Neoplasms, Hematologic
Interventions:   Drug: 200 mg LY2784544;   Drug: 400 mg LY2784544;   Drug: 600 mg LY2784544
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Not yet recruiting - verified May 2012

Condition:   Neuroblastoma
Interventions:   Biological: ch14.18 -NCI;   Biological: ch14.18-UTC;   Biological: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF);   Biological: Aldesleukin (IL-2);   Drug: Isotretinoin
Sponsors:   United Therapeutics;   United Therapeutics
Not yet recruiting - verified May 2012

Condition:   Neuroblastoma
Intervention:  
Sponsors:   New Approaches to Neuroblastoma Therapy Consortium;   New Approaches to Neuroblastoma Therapy Consortium
Recruiting - verified April 2012

Conditions:   Acromegaly;   Nonfunctioning Pituitary Tumor
Intervention:  
Sponsors:   Emory University;   Emory University
Recruiting - verified March 2012

Condition:   Bladder Cancer
Interventions:   Device: Monopolar electrocautery loop in Transurethral resection of bladder tumors;   Device: PK Button Vaporization Electrode in transurethral resection of bladder tumors
Sponsors:   Emory University;   Emory University;   Olympus
Not yet recruiting - verified March 2012

Condition:   Parathyroid Disease
Intervention:   Drug: FACBC
Sponsors:   Emory University;   David M. Schuster, MD
Not yet recruiting - verified April 2012

Condition:   Breast Cancer
Interventions:   Drug: pertuzumab;   Drug: trastuzumab [Herceptin];   Drug: pertuzumab;   Drug: trastuzumab [Herceptin];   Drug: vinorelbine
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified May 2012

Condition:   Colorectal Cancer
Intervention:  
Sponsors:   Epigenomics, Inc;   Epigenomics, Inc;   Kaiser Permanente;   Emory University
Not yet recruiting - verified April 2012

Conditions:   Pancreatic Cancer;   Rectal Cancer
Intervention:   Drug: capecitabine +ganetespib
Sponsors:   Emory University;   Emory University;   Synta Pharmaceuticals Corp.
Not yet recruiting - verified March 2012

Condition:   Cancer
Intervention:  
Sponsors:   Emory University;   Emory University
Recruiting - verified March 2012

Conditions:   Breast Cancer;   Colon Cancer
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified November 2011

Condition:   Breast Cancer
Interventions:   Drug: AC regimen;   Drug: TAC regimen;   Drug: cyclophosphamide;   Drug: docetaxel;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel
Sponsors:   National Cancer Institute (NCI);   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Multiple Myeloma
Interventions:   Drug: Panobinostat;   Drug: Carfilzomib
Sponsors:   Emory University;   Emory University;   Multiple Myeloma Research Consortium;   Novartis;   Onyx Therapeutics, Inc.
Recruiting - verified March 2012

Condition:   Breast Cancer
Interventions:   Device: 3Dimensional Mammography;   Device: 2D FFDM
Sponsors:   Fujifilm Medical Systems USA, Inc.;   Fujifilm Medical Systems USA, Inc.
Recruiting - verified March 2012

Condition:   Liver Cancer
Intervention:  
Sponsors:   Emory University;   Emory University
Recruiting - verified February 2012

Conditions:   Liver Cancer;   Portal Vein Thrombosis
Intervention:   Device: TheraSphere
Sponsors:   Emory University;   Emory University
Recruiting - verified April 2012

Condition:   Lung Cancer
Interventions:   Drug: linsitinib;   Drug: topotecan hydrochloride
Sponsors:   National Cancer Institute (NCI);   H. Lee Moffitt Cancer Center and Research Institute;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Actinic Keratosis
Interventions:   Procedure: Cryotherapy;   Drug: Vehicle;   Drug: Ingenol metabute
Sponsors:   LEO Pharma;   LEO Pharma
Recruiting - verified March 2012

Condition:   Locally Advanced HER2-Negative Breast Cancer
Interventions:   Drug: Eribulin Mesylate;   Drug: Cyclophosphamide;   Drug: Docetaxel
Sponsors:   Sarah Cannon Research Institute;   Sarah Cannon Research Institute;   Eisai Inc.
Not yet recruiting - verified March 2012

Conditions:   Melanoma;   Merkel Cell Carcinoma;   Squamous Cell Carcinoma;   Penile Carcinoma;   Urethral Carcinoma;   Extramammary Paget's Disease;   Scrotal Carcinoma;   Anal Cancer;   Vulvar Cancer;   Skin Cancer;   Lymphadenopathy
Interventions:   Procedure: Videoscopic procedure;   Procedure: Open, traditional approach
Sponsors:   Emory University;   Emory University
Recruiting - verified February 2012

Condition:   Carcinoma, Non-Small-Cell Lung
Interventions:   Drug: erlotinib;   Drug: afatinib
Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012

Condition:   Epithelial Ovarian Cancer
Interventions:   Biological: Placebo Study Agent;   Biological: Cvac
Sponsors:   Prima BioMed Ltd;   Prima BioMed Ltd
Recruiting - verified May 2012

Condition:   Melanoma (Skin)
Interventions:   Drug: Akt inhibitor MK2206;   Drug: selumetinib
Sponsors:   National Cancer Institute (NCI);   H. Lee Moffitt Cancer Center and Research Institute;   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Melanoma
Interventions:   Biological: Ipilimumab;   Biological: Ipilimumab
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified March 2012

Conditions:   Metastatic Pancreatic Adenocarcinoma;   Pancreatic Cancer;   Metastatic Pancreatic Cancer
Intervention:   Drug: 90Y-hPAM4
Sponsors:   Immunomedics, Inc.;   Immunomedics, Inc.
Recruiting - verified May 2012

Condition:   Melanoma
Interventions:   Drug: AZD6244 hydrogen sulfate;   Drug: MK-2206
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   H. Lee Moffitt Cancer Center and Research Institute;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Conditions:   Cancer;   Neoplasms;   Tumors
Intervention:   Drug: OSI-906 and Pemetrexed
Sponsors:   Emory University;   Emory University;   OSI Pharmaceuticals
Not yet recruiting - verified March 2012

Condition:   Lung Cancer
Intervention:   Drug: 18F-FACBC Radiotracer
Sponsors:   Emory University;   Emory University;   NIHON MEDI-PHYSICS CO.,LTD.
Recruiting - verified March 2012

Condition:   Non-Small Cell Lung Cancer
Interventions:   Drug: RO5490258;   Drug: bevacizumab [Avastin];   Drug: pemetrexed;   Drug: Placebo;   Drug: cisplatin/carboplatin;   Drug: paclitaxel
Sponsors:   Genentech;   Genentech
Not yet recruiting - verified January 2012

Conditions:   Glioblastoma;   Small Cell Glioblastoma;   Giant Cell Glioblastoma;   Gliosarcoma;   Glioblastoma With Oligodendroglial Component;   Recurrent Glioblastoma;   Relapsed Glioblastoma
Interventions:   Drug: Bevacizumab;   Drug: Rindopepimut (CDX-110) with GM-CSF;   Drug: KLH
Sponsors:   Celldex Therapeutics;   Celldex Therapeutics
Recruiting - verified May 2012

Condition:   Non-Small Cell Lung Cancer
Interventions:   Drug: GDC-0941;   Drug: carboplatin;   Drug: paclitaxel;   Drug: bevacizumab;   Drug: Placebo
Sponsors:   Genentech;   Genentech
Recruiting - verified February 2012

Condition:   Multiple Myeloma
Interventions:   Drug: Pomalidomide;   Drug: Bortezomib;   Drug: Dexamethasone
Sponsors:   Celgene Corporation;   Celgene Corporation;   Multiple Myeloma Research Consortium
Recruiting - verified April 2012

Condition:   Metastatic Pancreatic Cancer
Interventions:   Drug: MM-398;   Drug: 5 Fluorouracil;   Drug: Leucovorin
Sponsors:   Merrimack Pharmaceuticals;   Merrimack Pharmaceuticals
Recruiting - verified May 2012

Condition:   Cancer
Intervention:  
Sponsors:   Caris Science, Inc.;   Caris Science, Inc.
Recruiting - verified February 2012

Conditions:   Locally Recurrent Breast Cancer;   Metastatic Breast Cancer
Interventions:   Drug: NKTR-102;   Drug: Treatment of Physician's Choice (TPC)
Sponsors:   Nektar Therapeutics;   Nektar Therapeutics
Recruiting - verified April 2012

Conditions:   Cancer Survivor;   Human Papilloma Virus Infection
Interventions:   Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine;   Other: questionnaire administration;   Other: laboratory biomarker analysis;   Other: survey administration;   Other: medical chart review
Sponsors:   City of Hope Medical Center;   City of Hope Medical Center;   National Cancer Institute (NCI)
Not yet recruiting - verified December 2011

Condition:   Bladder Cancer
Interventions:   Drug: Genistein;   Drug: Sugar pill
Sponsors:   Emory University;   Emory University
Not yet recruiting - verified March 2012

Condition:   Breast Cancer
Interventions:   Drug: pertuzumab;   Drug: trastuzumab;   Drug: Aromatase Inhibitor;   Drug: Induction Chemotherapy
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified May 2012

Condition:   Multiple Myeloma
Interventions:   Drug: Ganetespib Dexamethasone;   Drug: Bortezomib;   Drug: Dexamethasone
Sponsors:   Emory University;   Emory University;   Multiple Myeloma Research Consortium
Recruiting - verified March 2012

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: mibefradil dihydrochloride;   Drug: temozolomide;   Other: 3'-deoxy-3'-[18F]fluorothymidine;   Other: pharmacological study
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI);   Tau Therapeutics LLC
Recruiting - verified April 2012

Conditions:   Acute Lymphoblastic Leukemia;   Precursor B-Cell Lymphoblastic Leukemia;   Precursor T-Cell Lymphoblastic Leukemia
Interventions:   Drug: Decitabine;   Drug: Vorinostat;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: Mitoxantrone;   Drug: Pegaspargase;   Drug: Methotrexate
Sponsors:   Therapeutic Advances in Childhood Leukemia Consortium;   Therapeutic Advances in Childhood Leukemia Consortium
Recruiting - verified March 2012

Condition:   Breast Cancer
Interventions:   Device: MammaPrint;   Device: BluePrint;   Device: TargetPrint;   Device: TheraPrint
Sponsors:   Agendia;   Agendia
Recruiting - verified April 2012

Conditions:   Breast Cancer;   Brain Metastases
Interventions:   Drug: GRN1005;   Drug: Trastuzumab
Sponsors:   Geron Corporation;   Geron Corporation
Recruiting - verified May 2012

Conditions:   Glioblastoma;   Small Cell Glioblastoma;   Giant Cell Glioblastoma;   Gliosarcoma;   Glioblastoma With Oligodendroglial Component
Interventions:   Drug: Rindopepimut (CDX-110) with GM-CSF;   Drug: Temozolomide;   Drug: KLH
Sponsors:   Celldex Therapeutics;   Celldex Therapeutics
Recruiting - verified May 2012

Condition:   Myelodysplastic Syndromes
Intervention:   Drug: ARRY-614, p38/Tie2 inhibitor; oral
Sponsors:   Array BioPharma;   Array BioPharma
Recruiting - verified March 2012

Condition:   Cancer
Interventions:   Drug: Axitinib;   Drug: Temsirolimus
Sponsors:   Emory University;   Emory University
Recruiting - verified March 2012

Condition:   Pancreatic Cancer
Interventions:   Drug: GS-6624;   Drug: GS-6624;   Drug: Placebo;   Drug: Gemcitabine;   Drug: Gemcitabine;   Drug: Gemcitabine;   Drug: Gemcitabine;   Drug: GS-6624
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified March 2012

Condition:   Solid Tumor
Intervention:   Drug: ARQ 092
Sponsors:   ArQule;   ArQule
Recruiting - verified November 2011

Condition:   Colorectal Cancer
Interventions:   Drug: GS-6624;   Drug: FOLFIRI;   Drug: GS-6624;   Drug: FOLFIRI;   Drug: GS-6624;   Drug: FOLFIRI;   Drug: Placebo;   Drug: FOLFIRI
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified March 2012

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions:   Drug: paclitaxel;   Drug: pazopanib hydrochloride;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Lung Cancer;   Cancer of Lung;   Pulmonary Cancer;   Pulmonary Neoplasms;   Carcinoma, Small Cell
Intervention:   Drug: Arsenic Trioxide
Sponsors:   Emory University;   Emory University;   Cephalon
Recruiting - verified May 2012

Conditions:   Esophageal Cancer;   Neoplasms, Esophageal
Interventions:   Drug: Everolimus;   Drug: Paclitaxel;   Drug: carboplatin;   Drug: cetuximab
Sponsors:   Emory University;   Emory University;   Novartis
Recruiting - verified March 2012

Condition:   Solid Tumors
Intervention:   Drug: BKM120 and RAD001
Sponsors:   Emory University;   Emory University;   Novartis Pharmaceuticals
Recruiting - verified February 2012

Condition:   Acute Lymphoblastic Leukemia
Intervention:   Drug: blinatumomab
Sponsors:   Micromet GmbH;   Micromet GmbH
Recruiting - verified February 2012

Condition:   Acute Lymphoblastic Leukemia
Intervention:   Drug: Blinatumomab
Sponsors:   Micromet GmbH;   Micromet GmbH
Recruiting - verified February 2012

Condition:   Leukemia, Pediatric
Intervention:   Drug: Dasatinib
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   Children's Oncology Group;   EsPhALL - European Intergroup Study on Post Induction Treatment of Philadelphia Positive Acute Lymphoblastic Leukaemia with Imatinib
Recruiting - verified April 2012

Conditions:   Breast Neoplasms;   Breast Cancer;   Breast Tumors;   Cancer of the Breast;   Neoplasms, Breast;   Tumors, Breast
Interventions:   Drug: Eribulin;   Drug: Doxorubicin;   Drug: Cyclophosphamide
Sponsors:   Emory University;   Emory University;   Eisai Inc.
Recruiting - verified December 2011

Condition:   Multiple Myeloma
Interventions:   Drug: Carfilzomib;   Drug: Pomalidomide;   Drug: Dexamethasone
Sponsors:   Academic Myeloma Consortium;   Academic Myeloma Consortium;   CORE Science Solutions;   Onyx Pharmaceuticals;   Celgene Corporation
Recruiting - verified February 2012

Condition:   Neuroendocrine Tumors
Interventions:   Drug: Pasireotide;   Procedure: Sir Sphere Radioembolization;   Drug: Everolimus
Sponsors:   Emory University;   Emory University;   Novartis
Recruiting - verified February 2012

Condition:   HIV Infections
Interventions:   Biological: Quadrivalent HPV Vaccine;   Biological: Placebo Vaccine
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012

Condition:   Small Cell Lung Carcinoma
Interventions:   Biological: Ipilimumab;   Biological: Placebo matching Ipilimumab;   Drug: Etoposide;   Drug: Cisplatin;   Drug: Carboplatin
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified October 2011

Condition:   Multiple Myeloma
Intervention:  
Sponsors:   Multiple Myeloma Research Foundation;   Multiple Myeloma Research Foundation;   Translational Genomics Research Institute, Phoenix, Arizona.;   Spectrum Health Hospitals;   Van Andel Research Institute;   Quintiles
Recruiting - verified May 2012

Conditions:   Benign Neoplasms, Brain;   Brain Cancer;   Brain Neoplasms, Benign;   Brain Neoplasms, Malignant;   Brain Tumor, Primary;   Brain Tumor, Recurrent;   Brain Tumors;   Intracranial Neoplasms;   Neoplasms, Brain;   Neoplasms, Intracranial;   Primary Brain Neoplasms;   Primary Malignant Brain Neoplasms;   Primary Malignant Brain Tumors;   Gliomas;   Glioblastoma
Intervention:   Drug: 5-ALA (Gliolan)
Sponsors:   Emory University;   Emory University
Recruiting - verified April 2012

Conditions:   Solid Tumour;   Adenocarcinoma of the Colon;   Adenocarcinoma of the Pancreas
Intervention:   Drug: CEP-37250/KHK2804
Sponsors:   Kyowa Hakko Kirin Pharma, Inc.;   Kyowa Hakko Kirin Pharma, Inc.;   Cephalon
Recruiting - verified February 2012

Conditions:   Cancer of Pancreas;   Cancer of the Pancreas;   Neoplasms, Pancreatic;   Pancreas Cancer;   Pancreas Neoplasms
Interventions:   Drug: Folfirinox;   Radiation: Stereotactic Body Radiotherapy (SBRT)
Sponsors:   Emory University;   Emory University
Recruiting - verified April 2012

Condition:   Smoldering Multiple Myeloma
Intervention:   Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   Abbott Biotherapeutics Corp.
Recruiting - verified February 2012

Conditions:   Estrogen Receptor Positive Tumor;   Breast Cancer
Intervention:   Drug: E7389 (eribulin mesylate) and capecitabine
Sponsors:   Eisai Inc.;   Eisai Inc.
Recruiting - verified April 2012

Conditions:   Non-small Cell Lung Cancer (NSCLC);   Stage IV NSCLC;   Metastatic NSCLC
Interventions:   Drug: Cabazitaxel-XRP6258;   Drug: Cabazitaxel-XRP6258
Sponsors:   University of Alabama at Birmingham;   University of Alabama at Birmingham;   Sanofi-Aventis
Recruiting - verified April 2012

Condition:   Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer
Interventions:   Drug: MEDI-573;   Drug: Aromatase Inhibitor
Sponsors:   MedImmune LLC;   MedImmune LLC
Recruiting - verified May 2012

Conditions:   Pancreatic Neoplasms;   Cholangiocarcinoma
Intervention:   Drug: Gemcitabine with TheraSphere
Sponsors:   Emory University;   Hyun Kevin Kim;   Emory University
Recruiting - verified April 2012

Condition:   Breast Cancer
Interventions:   Drug: fulvestrant;   Drug: GDC-0941;   Drug: GDC-0980;   Drug: placebo
Sponsors:   Genentech;   Genentech
Recruiting - verified April 2012

Condition:   Glioblastoma Multiforme
Intervention:   Drug: Temozolomide, bevacizumab and bortezomib
Sponsors:   Emory University;   Emory University
Recruiting - verified March 2012

Condition:   Breast Cancer
Interventions:   Biological: Ramucirumab (IMC-1121B);   Drug: Eribulin
Sponsors:   ImClone LLC;   ImClone LLC
Recruiting - verified May 2012

Conditions:   Uterine Fibroids;   Heavy Uterine Bleeding
Interventions:   Drug: placebo;   Drug: elagolix, elagolix sodium;   Drug: Placebo;   Drug: elagolix, elagolix sodium;   Other: Elagolix Dose 1 plus estradiol/norethindrone acetate;   Drug: Placebo Cohort 4;   Drug: Elagolix, elagolix sodium;   Drug: Elagolix, elagolix sodium
Sponsors:   Abbott;   Abbott;   Neurocrine Biosciences
Recruiting - verified April 2012

Conditions:   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer;   Liver Cancer
Interventions:   Drug: Akt inhibitor MK2206;   Genetic: mutation analysis;   Genetic: proteomic profiling;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   Arthur G. James Cancer Hospital & Richard J. Solove Research Institute;   National Cancer Institute (NCI)
Recruiting - verified August 2011

Conditions:   ER Positive, Her2 Negative Breast Cancer Patients;   Triple Negative Breast Cancer Patients
Interventions:   Drug: MM-121 (SAR256212) plus paclitaxel;   Drug: Paclitaxel
Sponsors:   Merrimack Pharmaceuticals;   Merrimack Pharmaceuticals;   Sanofi-Aventis
Recruiting - verified April 2012

Condition:   Breast Cancer
Interventions:   Drug: trastuzumab emtansine;   Drug: anti-cancer therapy
Sponsors:   Genentech;   Genentech
Recruiting - verified March 2012

Condition:   Metastatic Breast Cancer
Interventions:   Drug: LY2523355;   Drug: Ixabepilone;   Drug: pegfilgrastim;   Drug: filgrastim
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified May 2012

Conditions:   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions:   Drug: paclitaxel;   Drug: carboplatin;   Drug: vorinostat;   Other: placebo;   Other: laboratory biomarker analysis;   Other: immunohistochemistry staining method;   Genetic: protein analysis;   Genetic: gene expression analysis;   Genetic: proteomic profiling
Sponsors:   California Cancer Consortium;   California Cancer Consortium;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Bladder Cancer
Interventions:   Drug: Apaziquone;   Drug: Placebo
Sponsors:   Spectrum Pharmaceuticals, Inc;   Spectrum Pharmaceuticals, Inc;   Allergan
Recruiting - verified April 2012

Condition:   Lymphoma, B-Cell
Interventions:   Drug: RO50722759;   Drug: cyclophosphamide;   Drug: doxorubicin;   Drug: vincristine;   Drug: prednisone
Sponsors:   Genentech;   Genentech
Recruiting - verified May 2012

Condition:   Mantle Cell Lymphoma
Interventions:   Drug: Panobinostat;   Drug: Bortezomib
Sponsors:   Georgia Health Sciences University;   Anand Jillella;   Novartis Pharmaceuticals
Recruiting - verified January 2012

Conditions:   Lymphoblastic Leukemia, Acute, Childhood;   Myelogenous Leukemia, Acute, Childhood
Interventions:   Drug: AC220;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Methotrexate
Sponsors:   Therapeutic Advances in Childhood Leukemia Consortium;   Therapeutic Advances in Childhood Leukemia Consortium;   Ambit Biosciences Corporation
Recruiting - verified September 2011

Condition:   Metastatic Colorectal Cancer
Interventions:   Drug: bevacizumab;   Drug: MEGF0444A;   Drug: mFOLFOX6;   Drug: placebo
Sponsors:   Genentech;   Genentech
Recruiting - verified March 2012

Condition:   Metastatic Breast Cancer
Interventions:   Drug: eribulin mesylate;   Drug: eribulin mesylate;   Drug: eribulin mesylate, trastuzumab
Sponsors:   Sarah Cannon Research Institute;   Sarah Cannon Research Institute;   Eisai Inc.
Recruiting - verified March 2012

Conditions:   Cognitive/Functional Effects;   Leukemia;   Neurotoxicity;   Pain;   Therapy-related Toxicity
Interventions:   Drug: clofarabine;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: hydrocortisone sodium succinate;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: selective external radiation therapy
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Colorectal Neoplasms;   Digestive System Diseases;   Colonic Diseases;   Colorectal Cancer
Intervention:  
Sponsors:   Exact Sciences Corporation;   Exact Sciences Corporation
Recruiting - verified August 2011

Condition:   Lymphoma
Intervention:   Drug: SAR245409
Sponsors:   Sanofi-Aventis;   Sanofi-Aventis
Recruiting - verified May 2012

Conditions:   Indolent Non-Hodgkin Lymphoma;   Mantle Cell Lymphoma;   Chronic Lymphocytic Leukemia
Intervention:   Drug: SAR245409
Sponsors:   Sanofi-Aventis;   Sanofi-Aventis
Recruiting - verified April 2012

Conditions:   Brain Metastasis;   Neoplasm
Intervention:   Radiation: Radiosurgery dose escalation
Sponsors:   Emory University;   Emory University
Recruiting - verified March 2012

Conditions:   Leukemia;   Lymphoma
Interventions:   Drug: dexamethasone;   Drug: methotrexate;   Drug: mitoxantrone hydrochloride;   Drug: pegaspargase;   Drug: temsirolimus;   Drug: vincristine sulfate;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Pancreatic Cancer
Intervention:   Drug: dasatinib
Sponsors:   Otsuka Pharmaceutical Development & Commercialization, Inc.;   Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified February 2012

Condition:   Multiple Myeloma
Interventions:   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Dexamethasone;   Drug: Dexamethasone;   Biological: Elotuzumab (BMS-901608; HuLuc63);   Drug: Lenalidomide;   Drug: Lenalidomide
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   Abbott Biotherapeutics Corp.
Recruiting - verified October 2011

Condition:   HER-2 Positive Breast Cancer
Interventions:   Drug: eribulin;   Drug: carboplatin;   Drug: trastuzumab
Sponsors:   ACORN Research, LLC;   ACORN Research, LLC;   Eisai Inc.
Recruiting - verified January 2012

Condition:   Metastatic Clear Cell Renal Cell Carcinoma
Interventions:   Drug: LY2510924;   Drug: Sunitinib
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified April 2012

Conditions:   Arthralgia;   Breast Cancer;   Pain
Interventions:   Dietary Supplement: omega-3 fatty acid;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Lung Cancer
Interventions:   Drug: Topotecan;   Drug: OSI-906
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   H. Lee Moffitt Cancer Center and Research Institute;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Acute Myeloid Leukemia
Intervention:  
Sponsors:   Center for International Blood and Marrow Transplant Research;   Center for International Blood and Marrow Transplant Research;   Resource for Clinical Investigations in Blood and Marrow Transplantation (RCI-BMT);   Pediatric Blood and Marrow Transplant Consortium
Recruiting - verified May 2012

Conditions:   Cognitive/Functional Effects;   Fatigue;   Lymphoma;   Neurotoxicity;   Therapy-related Toxicity
Interventions:   Biological: rituximab;   Drug: bortezomib;   Drug: dexamethasone;   Drug: temsirolimus
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Prostate Cancer
Interventions:   Radiation: radiation therapy;   Radiation: selective external radiation therapy
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Leukemia
Interventions:   Drug: asparaginase;   Drug: bortezomib;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: etoposide;   Drug: mitoxantrone hydrochloride;   Drug: sorafenib tosylate
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Non-Small Cell Lung Cancer
Interventions:   Drug: bevacizumab;   Drug: carboplatin;   Drug: MEGF0444A;   Drug: paclitaxel;   Drug: placebo
Sponsors:   Genentech;   Genentech
Recruiting - verified March 2012

Condition:   Cancer
Interventions:   Drug: carboplatin;   Drug: paclitaxel;   Drug: veliparib;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   University of Pittsburgh;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Conditions:   Crohn's Disease;   IBD;   Colitis;   Inflammatory Bowel Disease
Interventions:   Drug: Group 2 ustekinumab 130 mg;   Drug: Group 3: ustekinumab approximately 6 mg/kg;   Drug: Group 1: Placebo
Sponsors:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.;   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified April 2012

Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome
Interventions:   Drug: Preparative Regimen;   Biological: NK Cell Product;   Drug: Interleukin-2;   Biological: Donor CD34+ Cells;   Biological: Anti-thymocyte globulin
Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2012

Conditions:   Bacterial Infection;   Leukemia;   Musculoskeletal Complications;   Neutropenia
Interventions:   Drug: levofloxacin;   Procedure: standard follow-up care
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Pain;   Advanced Cancer
Interventions:   Drug: Sativex®;   Drug: Placebo (GA-0034)
Sponsors:   GW Pharmaceuticals Ltd.;   GW Pharmaceuticals Ltd.;   Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified August 2011

Condition:   Breast Cancer
Interventions:   Drug: pertuzumab;   Drug: placebo;   Drug: trastuzumab [Herceptin];   Drug: Chemotherapy
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche;   Breast International Group;   Genentech
Recruiting - verified February 2012

Condition:   Lung Cancer, Non-Small Cell
Interventions:   Drug: GSK1120212;   Drug: docetaxel
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified May 2012

Condition:   Small Cell Lung Carcinoma
Intervention:   Drug: Amuvatinib
Sponsors:   Astex Pharmaceuticals;   Astex Pharmaceuticals
Recruiting - verified May 2012

Condition:   Acute Myelogenous Leukemia
Intervention:   Drug: R115777
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   H. Lee Moffitt Cancer Center and Research Institute;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Lymphoma
Interventions:   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate;   Other: R-CHOP regimen;   Other: laboratory biomarker analysis;   Radiation: fludeoxyglucose F 18;   Radiation: selective external radiation therapy;   Radiation: yttrium Y 90 ibritumomab tiuxetan
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Non-Small Cell Lung Cancer
Interventions:   Drug: bevacizumab [Avastin];   Drug: Standard of care treatment
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified May 2012

Conditions:   Hematological Malignancies;   Certain Lysosomal Storage and Peroxisomal Enzyme Deficiency Disorders;   Hurler Syndrome (MPS I);   Krabbe Disease (Globoid Leukodystrophy);   X-linked Adrenoleukodystrophy;   Primary Immunodeficiency Diseases;   Bone Marrow Failure;   Beta-thalassemia
Intervention:   Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Sponsors:   Center for International Blood and Marrow Transplant Research;   Center for International Blood and Marrow Transplant Research;   National Marrow Donor Program
Recruiting - verified April 2012

Condition:   Breast Cancer
Interventions:   Radiation: 3-dimensional conformal radiation therapy;   Radiation: accelerated radiation therapy;   Radiation: hypofractionated radiation therapy;   Radiation: intensity-modulated radiation therapy;   Radiation: whole breast irradiation
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Non-small Cell Lung Cancer Stage IIIB;   Non-small Cell Lung Cancer Stage IV;   Non-small Cell Lung Cancer Metastatic
Interventions:   Drug: Docetaxel;   Drug: Combination of ganetespib and docetaxel
Sponsors:   Synta Pharmaceuticals Corp.;   Synta Pharmaceuticals Corp.
Recruiting - verified November 2011

Condition:   Colon Cancer and Rectal Cancer
Interventions:   Drug: FOLFIRI;   Drug: E7820
Sponsors:   Eisai Inc.;   Eisai Inc.;   PharmaBio Development Inc.
Recruiting - verified May 2012

Condition:   Leukemia
Interventions:   Drug: alvocidib;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: idarubicin;   Drug: mitoxantrone hydrochloride
Sponsors:   National Cancer Institute (NCI);   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Brain and Central Nervous System Tumors;   Depression
Interventions:   Drug: temozolomide;   Drug: vorinostat;   Other: survey administration;   Procedure: magnetic resonance spectroscopic imaging
Sponsors:   National Cancer Institute (NCI);   Winship Cancer Institute of Emory University;   National Cancer Institute (NCI)
Recruiting - verified April 2011

Condition:   Advanced Liposarcoma or Leiomyosarcoma
Interventions:   Drug: Trabectedin;   Drug: Dacarbazine
Sponsors:   Janssen Research & Development, LLC;   Janssen Research & Development, LLC;   Pharma Mar, S.A.U.
Recruiting - verified May 2012

Condition:   Chemotherapy-Induced Thrombocytopenia
Intervention:   Drug: ONO-7746
Sponsors:   Ono Pharma;   Ono Pharma
Recruiting - verified April 2012

Condition:   Lung Cancer
Interventions:   Procedure: therapeutic conventional surgery;   Radiation: iodine I 125;   Radiation: stereotactic body radiation therapy
Sponsors:   National Cancer Institute (NCI);   American College of Surgeons;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Non-Small Cell Lung Cancer (NSCLC)
Interventions:   Drug: Dacomitinib (PF-00299804);   Drug: Active Comparator (erlotinib)
Sponsors:   Pfizer;   Pfizer
Recruiting - verified May 2012

Conditions:   Pain;   Advanced Cancer
Intervention:   Drug: Sativex®
Sponsors:   GW Pharmaceuticals Ltd.;   GW Pharmaceuticals Ltd.;   Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified April 2011

Condition:   Leukemia, Myelocytic, Acute
Interventions:   Drug: Fludarabine and Busulfan (Flu/Bu);   Drug: Fludarabine and Melphalan (Flu/Mel);   Drug: Busulfan and Fludarabine (Bu/Flu);   Drug: Busulfan and Cyclophosphamide (Bu/Cy);   Drug: Cyclophosphamide and Total Body Irradiation (Cy/TBI)
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network
Recruiting - verified March 2012

Conditions:   Chronic Leukemia;   Acute Leukemia;   Hodgkin's Disease;   Non-Hodgkin's Lymphoma;   Myelodysplastic Syndrome
Intervention:   Procedure: Peripheral Blood Stem Cell Transplant
Sponsors:   Northside Hospital, Inc.;   Northside Hospital, Inc.;   Blood and Marrow Transplant Group of Georgia
Recruiting - verified September 2011

Condition:   Multiple Myeloma
Interventions:   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Dexamethasone;   Drug: Dexamethasone;   Drug: Dexamethasone;   Biological: Elotuzumab (BMS-901608; HuLuc63);   Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   Abbott Biotherapeutics Corp.
Recruiting - verified October 2011

Condition:   Ovarian Cancer Recurrent
Interventions:   Drug: Ombrabulin (AVE8062);   Drug: Placebo;   Drug: Paclitaxel;   Drug: Carboplatin
Sponsors:   Sanofi-Aventis;   Sanofi-Aventis
Recruiting - verified May 2012

Conditions:   Multiple Myeloma;   Renal Insufficiency
Interventions:   Drug: BHQ880;   Drug: BHQ990
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified May 2012

Conditions:   Ewing's Sarcoma;   Osteosarcoma;   Astrocytoma;   Atypical Teratoid/Rhabdoid Tumor;   Ependymoma;   Germ Cell Tumor;   Glioma;   Medulloblastoma;   Rhabdoid Tumor;   Retinoblastoma;   Clear Cell Sarcoma;   Renal Cell Carcinoma;   Wilms Tumor;   Hepatoblastoma;   Neuroblastoma;   Rhabdomyosarcoma
Intervention:   Drug: sirolimus
Sponsors:   Emory University;   Emory University;   Children's Healthcare of Atlanta
Recruiting - verified October 2011

Condition:   Neuroblastoma
Interventions:   Biological: hu14.18-IL2 fusion protein;   Biological: sargramostim;   Drug: isotretinoin;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Multiple Myeloma
Interventions:   Drug: MLN9708 plus Melphalan and Prednisone;   Drug: MLN9708 plus Melphalan and Prednisone
Sponsors:   Millennium Pharmaceuticals, Inc.;   Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2012

Conditions:   Transitional Cell Carcinoma of Bladder;   Urethra Cancer;   Ureter Cancer;   Malignant Tumor of Renal Pelvis
Interventions:   Drug: Cisplatin;   Drug: Gemcitabine;   Biological: ALT-801
Sponsors:   Altor Bioscience Corporation;   Altor Bioscience Corporation;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   Advanced Solid Tumors;   Kidney Disease;   Renal Impairment
Interventions:   Drug: AMG 386 + Paclitaxel;   Drug: AMG 386
Sponsors:   Amgen;   Amgen
Recruiting - verified April 2012

Condition:   Soft Tissue Sarcoma
Interventions:   Drug: Eribulin mesylate 1.4 mg/m2 intravenous;   Drug: Dacarbazine of 850 mg/m2, or 1,000 mg/m2, or 1,200 mg/m2 IV
Sponsors:   Eisai Inc.;   Eisai Inc.
Recruiting - verified May 2012

Conditions:   Lymphoblastic Leukemia, Acute, Childhood;   Myelogenous Leukemia, Acute, Childhood;   Hodgkin's Disease;   Non-Hodgkin's Lymphoma
Interventions:   Drug: Panobinostat;   Drug: Cytarabine;   Drug: Panobinostat
Sponsors:   Therapeutic Advances in Childhood Leukemia Consortium;   Therapeutic Advances in Childhood Leukemia Consortium;   Novartis
Recruiting - verified November 2011

Conditions:   Diffuse Large B-cell Lymphoma;   de Novo DLBCL;   DLBCL Transformed From Indolent Lymphoma;   Follicular Grade 3 Lymphoma
Interventions:   Drug: Pixantrone + Rituximab;   Drug: Gemcitabine + Rituximab
Sponsors:   Cell Therapeutics;   Cell Therapeutics
Recruiting - verified May 2012

Condition:   Neuroblastoma
Intervention:   Drug: Isotretinoin
Sponsors:   Emory University;   Emory University;   Children's Healthcare of Atlanta
Recruiting - verified October 2011

Conditions:   Locally Advanced Malignant Neoplasm;   Malignant Solid Tumour
Intervention:   Biological: ALT-836 in combination with gemcitabine
Sponsors:   Altor Bioscience Corporation;   Altor Bioscience Corporation
Recruiting - verified September 2011

Conditions:   Prostate Cancer;   Prostatic Neoplasm
Intervention:   Drug: abiraterone acetate in combination with prednisone
Sponsors:   Janssen Biotech, Inc.;   Janssen Biotech, Inc.
Recruiting - verified May 2012

Conditions:   Relapsed/Refractory AML;   Relapsed/Refractory ALL;   Secondary AML/MDS;   Acute Leukemia of Ambiguous Lineage;   AML;   ALL
Intervention:   Drug: Plerixafor Dose Escalation
Sponsors:   Emory University;   Emory University;   Children's Healthcare of Atlanta;   Pediatric Oncology Experimental Therapeutics Investigation Consortium
Recruiting - verified January 2012

Conditions:   Advanced Prostate Cancer;   Prostatic Neoplasms
Intervention:   Biological: sipuleucel-T
Sponsors:   Dendreon;   Dendreon
Recruiting - verified March 2012

Conditions:   Head and Neck Cancer;   Precancerous Condition
Interventions:   Biological: cetuximab;   Drug: cisplatin
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Fungal Infection;   Leukemia;   Neutropenia
Interventions:   Drug: caspofungin acetate;   Drug: fluconazole
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Multiple Myeloma
Intervention:   Drug: ACY-1215
Sponsors:   Acetylon Pharmaceuticals Incorporated;   Acetylon Pharmaceuticals Incorporated;   The Leukemia and Lymphoma Society
Recruiting - verified April 2012

Condition:   Pulmonary Infiltrate New
Intervention:   Other: Microbiological analysis
Sponsors:   Northside Hospital, Inc.;   Northside Hospital, Inc.;   Blood and Marrow Transplant Group of Georgia
Recruiting - verified May 2012

Condition:   Colorectal Cancer Metastatic
Interventions:   Drug: Regorafenib (BAY 73-4506);   Drug: FOLFIRI;   Drug: Placebo;   Drug: FOLFIRI
Sponsors:   UNC Lineberger Comprehensive Cancer Center;   UNC Lineberger Comprehensive Cancer Center;   Bayer
Recruiting - verified April 2012

Condition:   Breast Cancer
Intervention:   Other: MRI
Sponsors:   Piedmont Healthcare;   Piedmont Healthcare
Recruiting - verified June 2011

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: BKM120 or Docetaxel;   Drug: BKM120 or Docetaxel or Pemetrexed
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified May 2012

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: Sapacitabine and decitabine;   Drug: Decitabine
Sponsors:   Cyclacel Pharmaceuticals, Inc.;   Cyclacel Pharmaceuticals, Inc.
Recruiting - verified November 2011

Condition:   Chronic Lymphocytic Leukemia
Interventions:   Drug: bendamustine;   Drug: cyclophosphamide;   Drug: Fludarabine;   Drug: RO5072759
Sponsors:   Genentech;   Genentech
Recruiting - verified March 2012

Conditions:   Intractable Pain;   Neoplasms
Interventions:   Biological: NP2;   Biological: Placebo
Sponsors:   Diamyd Inc;   Diamyd Inc;   Paragon Biomedical;   invivodata, Inc.
Recruiting - verified January 2012

Condition:   Prostatic Neoplasms
Interventions:   Drug: MDV3100;   Drug: Bicalutamide
Sponsors:   Astellas Pharma Inc;   Astellas Pharma Inc;   Medivation, Inc.
Recruiting - verified March 2012

Conditions:   Breast Cancer;   Depression;   Fatigue;   Sleep Disorders
Interventions:   Drug: metformin hydrochloride;   Genetic: DNA analysis;   Genetic: RNA analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: enzyme-linked immunosorbent assay;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Procedure: quality-of-life assessment
Sponsors:   National Cancer Institute (NCI);   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Anemia
Intervention:   Drug: LY2787106
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified April 2012

Conditions:   Head and Neck Neoplasms;   Cancer of the Head and Neck
Intervention:   Drug: Carboplatin, cetuximab and RAD001
Sponsors:   Emory University;   Emory University;   Novartis
Recruiting - verified November 2011

Condition:   Oral Mucositis
Interventions:   Device: MuGard;   Device: Control Rinse
Sponsors:   Access Pharmaceuticals, Inc.;   Access Pharmaceuticals, Inc.
Recruiting - verified April 2012

Condition:   Acute Myelogenous Leukemia
Intervention:   Biological: KIR genotype
Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota;   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Lymphoma, B-Cell
Interventions:   Drug: RO5072759;   Drug: rituximab [MabThera/Rituxan];   Drug: CHOP chemotherapy
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified May 2012

Condition:   Smoldering Multiple Myeloma
Intervention:   Drug: BHQ880
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified May 2012

Conditions:   Cognitive/Functional Effects;   Colorectal Cancer;   Neurotoxicity
Interventions:   Biological: bevacizumab;   Drug: capecitabine;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin
Sponsors:   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   National Cancer Institute (NCI);   Cancer and Leukemia Group B
Recruiting - verified February 2012

Condition:   Hepatocellular Carcinoma
Interventions:   Drug: ADI-PEG 20 (arginine deiminase formulated with polyethylene glycol);   Drug: Placebo
Sponsors:   Polaris Group;   Polaris Group
Recruiting - verified March 2012

Conditions:   Indolent Non-Hodgkin Lymphoma;   Follicular Lymphoma;   Small Lymphocytic Lymphoma;   Lymphoplasmacytoid Lymphoma;   Marginal Zone Lymphoma
Intervention:   Drug: CAL-101
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified April 2012

Condition:   Breast Cancer
Interventions:   Biological: trastuzumab;   Drug: cyclophosphamide;   Drug: docetaxel;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel
Sponsors:   National Cancer Institute (NCI);   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   Brain and Central Nervous System Tumors;   Lymphoma;   Lymphoproliferative Disorder;   Small Intestine Cancer;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Drug: imetelstat sodium;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Neoplasms;   Lymphomas
Intervention:   Drug: Belinostat
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified September 2011

Conditions:   Breast Neoplasms;   Breast Cancer;   Cancer of the Breast
Intervention:   Drug: Lapatinib and Everolimus
Sponsors:   Emory University;   Emory University
Recruiting - verified January 2012

Condition:   Breast Cancer
Interventions:   Drug: anastrozole;   Drug: exemestane;   Drug: letrozole;   Drug: systemic chemotherapy;   Drug: tamoxifen citrate
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Thyroid Cancer
Interventions:   Drug: Everolimus;   Drug: Pasireotide;   Drug: Everolimus and Pasireotide
Sponsors:   Emory University;   Emory University;   Novartis
Recruiting - verified April 2012

Condition:   Metastatic Pancreatic Cancer
Interventions:   Biological: bavituximab;   Drug: Gemcitabine
Sponsors:   Peregrine Pharmaceuticals;   Peregrine Pharmaceuticals
Recruiting - verified May 2012

Condition:   Breast Cancer
Intervention:   Drug: Eribulin Mesylate
Sponsors:   Eisai Inc.;   Eisai Inc.
Recruiting - verified March 2012

Condition:   Follicular Lymphoma
Intervention:   Drug: HCD122
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified March 2012

Condition:   Melanoma (Skin)
Interventions:   Biological: ipilimumab;   Biological: recombinant interferon alfa-2b
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Cancer;   Gastric Cancer
Intervention:   Drug: Akt inhibitor MK2206
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Pain
Interventions:   Drug: Sativex®;   Drug: Placebo (GA-0034)
Sponsors:   GW Pharmaceuticals Ltd.;   GW Pharmaceuticals Ltd.;   Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified May 2011

Conditions:   Breast Neoplasms;   Breast Cancer;   Breast Tumors;   Cancer of Breast;   Cancer of the Breast;   Human Mammary Carcinoma;   Neoplasms, Breast
Interventions:   Procedure: Remove tumor only;   Procedure: Removal of tumor and tissue
Sponsors:   Emory University;   Emory University
Recruiting - verified March 2012

Conditions:   Colorectal Neoplasms;   Digestive System Diseases;   Colonic Diseases;   Colorectal Cancer
Intervention:  
Sponsors:   Exact Sciences Corporation;   Exact Sciences Corporation
Recruiting - verified August 2011

Condition:   Herpes Zoster
Interventions:   Biological: V212;   Biological: Placebo
Sponsors:   Merck;   Merck
Recruiting - verified May 2012

Condition:   Prostate Cancer
Interventions:   Drug: Akt inhibitor MK2206;   Drug: bicalutamide;   Other: clinical observation
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Incurable Metastatic Colorectal Carcinoma;   Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Interventions:   Drug: PX-866 and cetuximab;   Drug: Cetuximab;   Drug: PX-866 and cetuximab;   Drug: Cetuximab
Sponsors:   Oncothyreon Inc.;   Oncothyreon Inc.
Recruiting - verified April 2012

Condition:   Multiple Myeloma, Plasma Cell Leukemia
Interventions:   Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous;   Drug: Bortezomib, proteasome inhibitor; intravenous;   Drug: Dexamethasone, steroid; oral;   Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
Sponsors:   Array BioPharma;   Array BioPharma
Recruiting - verified June 2011

Condition:   Breast Cancer
Interventions:   Procedure: palliative surgery;   Procedure: therapeutic conventional surgery;   Radiation: palliative radiation therapy;   Radiation: radiation therapy
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Hematologic Neoplasms
Intervention:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Sponsors:   Northside Hospital, Inc.;   Northside Hospital, Inc.;   Blood and Marrow Transplant Group of Georgia
Recruiting - verified March 2012

Condition:   Prostate Cancer
Interventions:   Behavioral: telephone-based intervention;   Other: counseling intervention;   Other: educational intervention;   Procedure: therapeutic dietary intervention
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Colorectal Cancer
Interventions:   Procedure: Colonoscopy;   Procedure: FIT
Sponsors:   Department of Veterans Affairs;   Department of Veterans Affairs
Not yet recruiting - verified April 2012

Conditions:   Stomach Cancer;   Esophageal Cancer
Interventions:   Biological: Ramucirumab;   Drug: Placebo;   Drug: Oxaliplatin;   Drug: Leucovorin;   Drug: 5-Fluorouracil
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified May 2012

Condition:   Chronic Myeloid Leukemia
Intervention:  
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   ICON Clinical Research
Recruiting - verified May 2012

Condition:   Breast Cancer
Interventions:   Biological: Ramucirumab DP;   Biological: IMC-18F1;   Drug: Capecitabine
Sponsors:   ImClone LLC;   ImClone LLC
Recruiting - verified May 2012

Condition:   Multiple Myeloma
Interventions:   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Dexamethasone (Oral);   Drug: Dexamethasone (IV);   Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   Abbott Biotherapeutics Corp.
Recruiting - verified May 2012

Condition:   Prostate Cancer
Intervention:   Drug: tasquinimod
Sponsors:   Active Biotech AB;   Active Biotech AB
Recruiting - verified April 2012

Conditions:   Brain and Central Nervous System Tumors;   Kidney Cancer;   Sarcoma
Interventions:   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: topotecan hydrochloride;   Drug: vincristine sulfate
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Brain and Central Nervous System Tumors;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Small Intestine Cancer;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Drug: Akt inhibitor MK2206;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2012

Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Acute Myeloid Leukemia/Transient Myeloproliferative Disorder;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Grade III Lymphomatoid Granulomatosis;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia With Excess Blasts;   Refractory Chronic Lymphocytic Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Hodgkin Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Childhood Small Noncleaved Cell Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Multiple Myeloma;   Stage I Mycosis Fungoides/Sezary Syndrome;   Stage I Small Lymphocytic Lymphoma;   Stage II Adult Hodgkin Lymphoma;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage II Childhood Hodgkin Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Childhood Small Noncleaved Cell Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Multiple Myeloma;   Stage II Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Childhood Small Noncleaved Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Multiple Myeloma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Hodgkin Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Childhood Small Noncleaved Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   Stage IV Small Lymphocytic Lymphoma;   Testicular Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies;   Waldenström Macroglobulinemia
Interventions:   Procedure: peripheral blood stem cell transplantation;   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Drug: cyclosporine;   Drug: sirolimus;   Drug: mycophenolate mofetil;   Other: flow cytometry;   Genetic: fluorescence in situ hybridization;   Genetic: polymerase chain reaction;   Procedure: allogeneic hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis;   Genetic: cytogenetic analysis
Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Islet Cell Tumor;   Pancreatic Cancer
Interventions:   Biological: bevacizumab;   Drug: everolimus;   Drug: octreotide acetate
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Non-Small-Cell Lung Carcinoma
Interventions:   Drug: Pemetrexed;   Drug: Cisplatin;   Drug: Cixutumumab
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company;   ImClone LLC
Recruiting - verified April 2012

Condition:   Metastatic Pancreatic Adenocarcinoma
Intervention:   Drug: CO-1.01
Sponsors:   Clovis Oncology, Inc.;   Clovis Oncology, Inc.
Recruiting - verified March 2012

Conditions:   Cognitive/Functional Effects;   Metastatic Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Procedure: cognitive assessment;   Procedure: quality-of-life assessment;   Radiation: intensity-modulated radiation therapy;   Radiation: whole-brain radiation therapy
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Breast Cancer
Interventions:   Drug: BMS-754807;   Drug: letrozole
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   Mayo Clinic
Recruiting - verified December 2011

Condition:   Colorectal Cancer
Interventions:   Drug: Panitumumab;   Drug: Oxaliplatin;   Drug: Irinotecan;   Drug: Leucovorin;   Drug: 5-Fluorouracil
Sponsors:   Sarah Cannon Research Institute;   Sarah Cannon Research Institute;   Amgen
Recruiting - verified July 2011

Conditions:   Renal Cell Carcinoma;   Cancer
Interventions:   Drug: pazopanib;   Drug: placebo
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified May 2012

Conditions:   Leukemia;   Acute Lymphoblastic Leukemia;   ALL
Intervention:   Drug: rituximab
Sponsors:   Emory University;   Emory University
Recruiting - verified January 2012

Condition:   Head and Neck Cancer
Interventions:   Drug: cisplatin;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Chronic Myelogenous Leukemia in Chronic Phase
Intervention:   Drug: nilotinib
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Conditions:   Prostate Neoplasms;   Genital Neoplasms, Male;   Urogenital Neoplasms;   Genital Diseases, Male
Intervention:   Drug: Abiraterone Acetate
Sponsors:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.;   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Available - verified April 2012

Condition:   Solid Organ Malignancies
Intervention:   Drug: Lenalidomide; Everolimus (RAD001)
Sponsors:   Emory University;   Emory University;   Celgene Corporation;   Novartis
Recruiting - verified February 2012

Condition:   Brain and Central Nervous System Tumors
Interventions:   Biological: bevacizumab;   Drug: irinotecan hydrochloride;   Drug: temozolomide
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Sarcoma
Interventions:   Biological: bevacizumab;   Drug: cyclophosphamide;   Drug: temsirolimus;   Drug: vinorelbine tartrate
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Breast Cancer
Interventions:   Drug: Sorafenib(Nexavar, BAY43-9006) / Capecitabine;   Drug: Placebo / Capecitabine
Sponsors:   Bayer;   Bayer;   Onyx Therapeutics, Inc.
Recruiting - verified April 2012

Condition:   Neoplasm Metastasis
Intervention:   Radiation: VMAT
Sponsors:   Emory University;   Emory University
Recruiting - verified March 2012

Condition:   NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions:   Drug: U3-1287;   Drug: Erlotinib
Sponsors:   Daiichi Sankyo Inc.;   Daiichi Sankyo Inc.
Recruiting - verified May 2012

Condition:   Lymphoma
Interventions:   Biological: rituximab;   Drug: bendamustine hydrochloride;   Drug: bortezomib;   Drug: lenalidomide
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Metastatic Renal Cell Carcinoma
Interventions:   Drug: Dovitinib;   Drug: Sorafenib
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Condition:   Multiple Myeloma
Interventions:   Drug: Lenalidomide;   Drug: Bortezomib;   Drug: Dexamethasone;   Procedure: Autologous Stem Cell Transplant
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   Celgene Corporation;   Millennium Pharmaceuticals, Inc.;   Massachusetts General Hospital;   Beth Israel Deaconess Medical Center;   Emory University;   University of Michigan;   Fox Chase Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Fred Hutchinson Cancer Research Center;   Barbara Ann Karmanos Cancer Institute;   Duke University;   University of California, San Francisco;   University of Chicago;   M.D. Anderson Cancer Center;   UNC Lineberger Comprehensive Cancer Center
Recruiting - verified July 2011

Condition:   Neuroblastoma
Interventions:   Drug: isotretinoin;   Drug: vorinostat;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   New Approaches to Neuroblastoma Therapy Consortium;   National Cancer Institute (NCI)
Recruiting - verified August 2011

Conditions:   AML;   ALL;   CML in Blast Crisis;   High-Risk MDS;   Multiple Myeloma
Intervention:   Drug: TG02 citrate
Sponsors:   Tragara Pharmaceuticals, Inc.;   Tragara Pharmaceuticals, Inc.
Recruiting - verified December 2011

Condition:   Kidney Cancer
Interventions:   Biological: bevacizumab;   Drug: everolimus;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   Diarrhea;   Gastrointestinal Complications;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: sulfasalazine;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Cancer
Interventions:   Biological: trastuzumab;   Drug: carboplatin;   Drug: paclitaxel
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Breast Cancer
Interventions:   Drug: Tamoxifen Citrate;   Drug: Placebo
Sponsors:   City of Hope Medical Center;   City of Hope Medical Center;   National Cancer Institute (NCI);   St. Jude Children's Research Hospital;   University Health Network, Toronto;   Emory University;   University of Michigan
Recruiting - verified February 2012

Conditions:   Breast Cancer;   Breast Tumors;   Breast Neoplasms
Intervention:   Drug: Decitabine, LHB589, Tamoxifen
Sponsors:   Emory University;   Emory University;   Novartis;   Eisai Inc.
Recruiting - verified May 2012

Condition:   Breast Cancer
Intervention:   Drug: Sorafenib
Sponsors:   Emory University;   Emory University;   Onyx Pharmaceuticals;   Bayer
Recruiting - verified April 2012

Condition:   Basal Cell Carcinoma
Interventions:   Drug: vismodegib (GDC-0449);   Drug: vismodegib (GDC-0449);   Drug: vismodegib (GDC-0449)
Sponsors:   Genentech;   Genentech
Recruiting - verified May 2012

Condition:   Lymphoma, Follicular
Interventions:   Biological: Ofatumumab;   Biological: Rituximab
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified May 2012

Condition:   Solid Tumor
Interventions:   Drug: docetaxel;   Drug: 1-Methyl-D-trytophan
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   H. Lee Moffitt Cancer Center and Research Institute;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Condition:   Prostate Cancer
Interventions:   Drug: Custirsen Sodium, Docetaxel, Prednisone;   Drug: Docetaxel, Prednisone
Sponsors:   Teva Pharmaceutical Industries;   Teva Pharmaceutical Industries;   OncoGenex Technologies
Recruiting - verified May 2012

Conditions:   Leukemia;   Acute Myeloid Leukemia;   Acute Nonlymphocytic Leukemia
Interventions:   Drug: vosaroxin and cytarabine;   Drug: placebo and cytarabine
Sponsors:   Sunesis Pharmaceuticals;   Sunesis Pharmaceuticals
Recruiting - verified April 2012

Condition:   Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
Interventions:   Drug: OSI-906;   Drug: erlotinib;   Drug: placebo
Sponsors:   Astellas Pharma Inc;   Astellas Pharma Inc
Recruiting - verified April 2012

Conditions:   Juvenile Pilcytic Astrocytoma (JPA);   Pleomorphic JPA;   Diffuse Astrocytoma (Fibrillary, Gemistocytic, Giant Cell, or Pleomorphic Xanthoastrocytoma);   Low Grade Oligoastrocytoma;   Low Grade Oligodendroglioma;   Low Grade Glioma NOS
Intervention:   Drug: Poly ICLC
Sponsors:   University of California, San Diego;   University of California, San Diego;   Emory University
Recruiting - verified June 2011

Condition:   Leukemia
Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: thioguanine;   Drug: vincristine sulfate
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Solid Tumor Malignancies
Intervention:   Drug: STA-9090 (ganetespib) with Docetaxel
Sponsors:   Synta Pharmaceuticals Corp.;   Synta Pharmaceuticals Corp.
Recruiting - verified July 2011

Condition:   Chronic Lymphocytic Leukemia (CLL)
Interventions:   Other: TRU-016 and bendamustine;   Other: TRU-016 and bendamustine;   Drug: Bendamustine
Sponsors:   Emergent Product Development Seattle LLC;   Emergent Product Development Seattle LLC
Recruiting - verified February 2012

Condition:   Breast Cancer
Interventions:   Drug: bevacizumab;   Drug: MetMAb;   Drug: paclitaxel;   Drug: placebo
Sponsors:   Genentech;   Genentech;   Hoffmann-La Roche
Recruiting - verified March 2012

Condition:   Colorectal Cancer
Interventions:   Biological: Ramucirumab;   Drug: Irinotecan;   Biological: Placebo;   Drug: Folinic Acid;   Drug: 5-Fluorouracil
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company;   ImClone LLC
Recruiting - verified May 2012

Condition:   Prostate Cancer
Intervention:   Drug: ARN-509
Sponsors:   Aragon Pharmaceuticals, Inc.;   Aragon Pharmaceuticals, Inc.
Recruiting - verified March 2012

Condition:   Pediatric Acute Myelogenous Leukemia (AML)
Interventions:   Drug: Decitabine;   Drug: Decitabine
Sponsors:   Eisai Inc.;   Eisai Inc.
Recruiting - verified April 2012

Conditions:   Pancreatic Neoplasms;   Pancreatic Cancer
Interventions:   Drug: Gemcitabine and cisplatin;   Drug: Gemcitabine / Cisplatin
Sponsors:   Emory University;   Emory University
Recruiting - verified May 2012

Condition:   Gastric Cancer
Interventions:   Biological: Ramucirumab DP;   Drug: Placebo;   Drug: Paclitaxel
Sponsors:   ImClone LLC;   ImClone LLC
Recruiting - verified December 2011

Condition:   Non Small Cell Lung Cancer
Interventions:   Drug: Docetaxel;   Biological: Ramucirumab;   Drug: Placebo
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company;   ImClone LLC
Recruiting - verified May 2012

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Drug: ruxolitinib phosphate;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Soft Tissue Sarcoma
Interventions:   Drug: doxorubicin in combination with palifosfamide-tris;   Drug: doxorubicin in combination with placebo
Sponsors:   ZIOPHARM;   ZIOPHARM
Recruiting - verified April 2012

Condition:   Carcinoma, Squamous Cell of the Head and Neck
Interventions:   Biological: REOLYSIN;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Placebo
Sponsors:   Oncolytics Biotech;   Oncolytics Biotech
Recruiting - verified March 2012

Condition:   Ovarian Cancer
Interventions:   Drug: EC145;   Drug: Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®);   Drug: placebo;   Drug: EC20
Sponsors:   Endocyte;   Endocyte
Recruiting - verified March 2012

Conditions:   Head and Neck Cancer;   Mucositis;   Oral Complications of Radiation Therapy;   Pain
Interventions:   Drug: doxepin hydrochloride;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Neoplasms, Breast
Interventions:   Drug: lapatinib;   Drug: trastuzumab;   Drug: Aromatase inhibitor;   Drug: lapatinib
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified May 2012

Conditions:   Brain and Central Nervous System Tumors;   Childhood Germ Cell Tumor;   Kidney Cancer;   Leukemia;   Liver Cancer;   Neuroblastoma;   Sarcoma
Interventions:   Drug: alisertib;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Non Squamous Lung Cancer
Interventions:   Drug: treatment;   Drug: treatment
Sponsors:   Pfizer;   Pfizer
Recruiting - verified April 2012

Conditions:   Minimal Residual Disease;   Leukemia, Lymphoblastic, Acute;   Leukemia, Myelogenous, Acute
Interventions:   Drug: Clofarabine;   Drug: Cytarabine;   Drug: Methotrexate;   Drug: Cytarabine
Sponsors:   Therapeutic Advances in Childhood Leukemia Consortium;   Therapeutic Advances in Childhood Leukemia Consortium;   Genzyme
Recruiting - verified November 2011

Condition:   Cancer
Intervention:  
Sponsors:   St. Jude Children's Research Hospital;   St. Jude Children's Research Hospital;   National Institutes of Health (NIH);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified February 2012

Condition:   Colorectal Cancer
Interventions:   Drug: celecoxib;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Breast Cancer
Interventions:   Drug: exemestane;   Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Drug: goserelin acetate
Sponsors:   National Cancer Institute (NCI);   H. Lee Moffitt Cancer Center and Research Institute;   National Cancer Institute (NCI)
Recruiting - verified June 2011

Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Cancer
Interventions:   Biological: cixutumumab;   Drug: paclitaxel
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified June 2011

Condition:   Non-small Cell Lung Cancer
Intervention:  
Sponsors:   Washington University School of Medicine;   Jennifer Bell;   University of Virginia;   University of North Carolina;   Emory University
Recruiting - verified October 2011

Condition:   Intraocular Melanoma
Interventions:   Drug: selumetinib;   Drug: temozolomide
Sponsors:   National Cancer Institute (NCI);   Memorial Sloan-Kettering Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Leukemia
Interventions:   Genetic: DNA ploidy analysis;   Genetic: chromosomal translocation analysis;   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization;   Other: cytology specimen collection procedure;   Other: flow cytometry;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Sarcoma
Interventions:   Biological: Trivalent ganglioside vaccine;   Biological: OPT-821
Sponsors:   MabVax Therapeutics, Inc.;   MabVax Therapeutics, Inc.
Recruiting - verified March 2012

Conditions:   Lymphoma;   HIV
Intervention:   Procedure: Autologous transplant
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network
Recruiting - verified January 2012

Condition:   Endometrial Cancer
Interventions:   Drug: cediranib maleate;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified November 2011

Condition:   Hepatocellular Carcinoma
Interventions:   Biological: Placebo;   Biological: Ramucirumab DP (IMC-1121B)
Sponsors:   ImClone LLC;   ImClone LLC
Recruiting - verified February 2012

Condition:   Lymphoma
Interventions:   Biological: bleomycin sulfate;   Drug: ABVD regimen;   Drug: BEACOPP regimen;   Drug: cyclophosphamide;   Drug: dacarbazine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: prednisone;   Drug: procarbazine hydrochloride;   Drug: vinblastine sulfate;   Drug: vincristine sulfate;   Other: laboratory biomarker analysis;   Procedure: computed tomography;   Radiation: fludeoxyglucose F 18;   Radiation: radiation therapy
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Thrombocytopaenia
Interventions:   Drug: Eltrombopag olamine;   Other: Placebo
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified April 2012

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: gamma-secretase inhibitor RO4929097;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: adjuvant therapy;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Breast Neoplasms
Interventions:   Drug: BIBW 2992;   Drug: trastuzumab;   Drug: vinorelbine;   Drug: vinorelbine
Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012

Condition:   Kidney Cancer
Interventions:   Drug: everolimus;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   Medulloblastoma,;   Rhabdomyosarcoma,;   Neuroblastoma,;   Hepatoblastoma,;   High Grade Glioma,;   Astrocytoma
Intervention:   Drug: LDE225
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Condition:   Cancer
Intervention:  
Sponsors:   St. Jude Children's Research Hospital;   St. Jude Children's Research Hospital;   National Cancer Institute (NCI);   Fred Hutchinson Cancer Research Center;   Nationwide Children's Hospital;   M.D. Anderson Cancer Center;   University of Southern California;   Children's Hospital Medical Center, Cincinnati
Recruiting - verified April 2012

Conditions:   Lymphoma, Non-Hodgkin;   Hodgkin Disease;   Multiple Myeloma
Interventions:   Drug: TXA127;   Drug: Placebo
Sponsors:   US Biotest, Inc.;   US Biotest, Inc.;   Tarix Pharmaceuticals
Recruiting - verified April 2012

Condition:   Breast Cancer
Interventions:   Drug: trastuzumab emtansine;   Drug: pertuzumab;   Drug: pertuzumab-placebo;   Drug: trastuzumab [Herceptin];   Drug: docetaxel;   Drug: paclitaxel
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche;   Genentech
Recruiting - verified March 2012

Condition:   Lung Cancer
Interventions:   Biological: bevacizumab;   Drug: pemetrexed disodium
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Multiple Myeloma
Interventions:   Drug: Lenalidomide;   Drug: lenalidomide, bortezomib and dexamethasone;   Drug: Lenalidomide
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Peripheral T-cell Lymphoma
Intervention:  
Sponsors:   Allos Therapeutics;   Allos Therapeutics
Recruiting - verified December 2011

Condition:   Breast Cancer
Interventions:   Drug: metformin hydrochloride;   Other: placebo
Sponsors:   NCIC Clinical Trials Group;   NCIC Clinical Trials Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Cervical Cancer
Interventions:   Drug: cisplatin;   Radiation: external beam radiation therapy;   Radiation: intensity-modulated radiation therapy
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   Cancer of Head and Neck;   Neoplasms, Head and Neck
Intervention:   Drug: Erlotinib and Green Tea Polyphenon E
Sponsors:   Emory University;   Emory University;   OSI Pharmaceuticals;   Polyphenon Pharma
Recruiting - verified October 2011

Conditions:   Chemotherapeutic Agent Toxicity;   Colorectal Cancer;   Neuropathy;   Neurotoxicity
Interventions:   Drug: calcium gluconate;   Drug: magnesium sulfate;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Acute Myeloid Leukemia (AML)
Interventions:   Drug: Elacytarabine;   Drug: Investigator's Choice
Sponsors:   Clavis Pharma;   Clavis Pharma
Recruiting - verified April 2012

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: vincristine sulfate;   Other: clinical observation;   Radiation: 3-dimensional conformal radiation therapy
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Disease, Hodgkin
Interventions:   Drug: brentuximab vedotin;   Drug: placebo
Sponsors:   Seattle Genetics, Inc.;   Seattle Genetics, Inc.;   Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012

Conditions:   Acute Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   Chronic Myelogenous Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Myelodysplasia
Interventions:   Drug: ABT-348;   Drug: ABT-348;   Drug: ABT-348 and azacitidine
Sponsors:   Abbott;   Abbott
Recruiting - verified May 2012

Conditions:   Myeloma;   Lymphoma
Intervention:   Drug: Plerixafor
Sponsors:   Emory University;   Emory University;   Genzyme
Recruiting - verified March 2012

Condition:   Head and Neck Neoplasms
Interventions:   Drug: Pemetrexed;   Drug: Cetuximab;   Drug: Carboplatin;   Drug: Cisplatin
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified October 2011

Condition:   Squamous Cell Lung Cancer
Interventions:   Drug: gemcitabine/carboplatin;   Drug: gemcitabine/carboplatin plus Iniparib
Sponsors:   Sanofi-Aventis;   Sanofi-Aventis;   BiPar Sciences
Recruiting - verified March 2012

Condition:   Multiple Myeloma
Intervention:   Drug: hLL1-DOX (the doxorubicin conjugate of milatuzumab)
Sponsors:   Immunomedics, Inc.;   Immunomedics, Inc.
Recruiting - verified February 2012

Conditions:   Cognitive/Functional Effects;   Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions:   Drug: systemic chemotherapy;   Other: questionnaire administration;   Procedure: assessment of therapy complications;   Procedure: cognitive assessment;   Procedure: quality-of-life assessment
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified October 2011

Condition:   Head and Neck Cancer
Interventions:   Drug: cetuximab;   Drug: Cisplatin;   Drug: Carboplatin;   Drug: 5-fluorouracil
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified May 2012

Condition:   Colorectal Cancer
Interventions:   Biological: cetuximab;   Biological: ramucirumab;   Drug: irinotecan hydrochloride
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Multiple Myeloma
Intervention:  
Sponsors:   Celgene Corporation;   Celgene Corporation
Recruiting - verified June 2011

Condition:   Chronic Lymphocytic Leukemia
Intervention:  
Sponsors:   Celgene Corporation;   Celgene Corporation
Recruiting - verified March 2011

Conditions:   Lymphoma, Non-Hodgkin;   Lymphoma, Follicular
Interventions:   Drug: Ofatumumab and Bendamustine infusions (Arm A);   Drug: Bendamustine infusion (Arm B)
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified March 2012

Conditions:   Non-Hodgkin's Lymphoma;   Mantle Cell Lymphoma
Intervention:   Drug: bendamustine and rituximab
Sponsors:   Teva Pharmaceutical Industries;   Cephalon
Recruiting - verified May 2012

Condition:   Breast Cancer
Interventions:   Drug: Placebo;   Drug: Denosumab
Sponsors:   Amgen;   Amgen;   Daiichi Sankyo Inc.
Recruiting - verified May 2012

Condition:   Prostate Cancer
Interventions:   Drug: Ipilimumab;   Drug: Placebo
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified March 2012

Condition:   Lung Cancer
Interventions:   Radiation: prophylactic cranial irradiation;   Radiation: selective external radiation therapy
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Sarcoma
Interventions:   Biological: cixutumumab;   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: irinotecan hydrochloride;   Drug: temozolomide;   Drug: vincristine sulfate
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Ovarian Cancer;   Non Small Cell Lung Cancer;   Prostate Cancer;   Colorectal Cancer;   Gastric Cancer;   Esophageal Cancer;   Cancer of Head and Neck
Interventions:   Drug: LY2523355;   Drug: pegfilgrastim
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified May 2012

Condition:   Ovarian Cancer
Interventions:   Biological: bleomycin sulfate;   Drug: carboplatin;   Drug: cisplatin;   Drug: etoposide phosphate;   Drug: paclitaxel
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Breast Neoplasms;   Breast Cancer;   Breast Tumors
Interventions:   Drug: Neratinib;   Drug: ABT-888;   Drug: Standard Therapy;   Drug: AMG 386;   Drug: AMG 479 (Ganitumab) plus Metformin
Sponsors:   Foundation for the National Institutes of Health;   Foundation for the National Institutes of Health
Recruiting - verified December 2011

Condition:   Non-Small-Cell Lung Cancer
Interventions:   Drug: Carboplatin;   Drug: Pemetrexed;   Drug: Panitumumab
Sponsors:   Sarah Cannon Research Institute;   Sarah Cannon Research Institute;   Amgen
Recruiting - verified October 2011

Condition:   Lung Cancer
Interventions:   Drug: carboplatin;   Drug: celecoxib;   Drug: gemcitabine hydrochloride;   Drug: pemetrexed disodium;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Neuroblastoma
Interventions:   Biological: aldesleukin;   Biological: monoclonal antibody Ch14.18;   Biological: sargramostim;   Drug: isotretinoin;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified April 2011

Condition:   Leukemia
Interventions:   Drug: clofarabine;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: decitabine;   Other: clinical observation
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Condition:   Metastatic Breast Cancer
Intervention:   Drug: Amrubicin
Sponsors:   Sarah Cannon Research Institute;   Sarah Cannon Research Institute;   Celgene Corporation
Recruiting - verified July 2011

Condition:   Leukaemia, Lymphocytic, Chronic
Interventions:   Biological: Ofatumumab;   Other: No Intervention
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified May 2012

Condition:   Small Cell Lung Cancer
Intervention:   Drug: LY2523355
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified February 2012

Condition:   Recurrent or Refractory Pediatric Ependymoma
Interventions:   Drug: erlotinib;   Drug: etoposide
Sponsors:   OSI Pharmaceuticals;   OSI Pharmaceuticals;   Astellas Pharma Global Development, Inc.
Recruiting - verified February 2012

Condition:   Lymphoma
Interventions:   Drug: Bendamustine;   Drug: Bortezomib;   Drug: Rituximab
Sponsors:   Sarah Cannon Research Institute;   Sarah Cannon Research Institute;   Millennium Pharmaceuticals, Inc.;   Cephalon
Recruiting - verified July 2011

Condition:   Multiple Myeloma
Interventions:   Drug: Panobinostat;   Drug: Bortezomib
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Condition:   Liver Cancer
Interventions:   Drug: doxorubicin hydrochloride;   Drug: sorafenib tosylate
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified September 2011

Condition:   Neuroblastoma
Interventions:   Drug: Vorinostat;   Radiation: 131- I Metaiodobenzylguanidine;   Procedure: Peripheral Blood Stem Cell Infusion;   Drug: Filgrastim
Sponsors:   New Approaches to Neuroblastoma Therapy Consortium;   New Approaches to Neuroblastoma Therapy Consortium;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Pancreatic Cancer
Interventions:   Drug: capecitabine;   Drug: erlotinib hydrochloride;   Drug: fluorouracil;   Drug: gemcitabine hydrochloride;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Brain Cancer
Intervention:   Other: cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Children's Healthcare of Atlanta;   Dana-Farber Cancer Institute;   M.D. Anderson Cancer Center;   Phoenix Children's Hospital;   Alberta Children's Hospital;   University of Colorado, Denver;   Seattle Children's Hospital;   Johns Hopkins University;   Children's Mercy Hospital-Kansas City, MO;   MD Anderson Cancer Center Orlando at Arnold Palmer Hospital for Children
Recruiting - verified March 2012

Conditions:   Colorectal Cancer;   Precancerous Condition
Interventions:   Drug: rosuvastatin;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   Endometrial Cancer;   Endometrial Neoplasms
Intervention:   Drug: XL147 (SAR245408)
Sponsors:   Sanofi-Aventis;   Sanofi-Aventis
Recruiting - verified April 2012

Conditions:   Breast Cancer;   Cardiac Toxicity
Interventions:   Drug: carvedilol phosphate extended-release capsule;   Drug: lisinopril;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   University of South Florida;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Breast Cancer
Intervention:   Other: ChemoFX Assay
Sponsors:   Precision Therapeutics;   Precision Therapeutics;   Department of Defense
Recruiting - verified December 2011

Condition:   Sarcoma
Interventions:   Biological: bevacizumab;   Biological: filgrastim;   Biological: pegfilgrastim;   Drug: docetaxel;   Drug: gemcitabine hydrochloride;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Leukemia
Interventions:   Biological: alemtuzumab;   Biological: rituximab
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   HER2/Neu Over-expressing Locally Advanced Breast Cancer;   Metastatic Breast Cancer
Interventions:   Drug: everolimus, vinorelbine, trastuzumab;   Drug: Placebo + vinorelbine + trastuzumab
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified May 2012

Condition:   Liver Cancer
Interventions:   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: doxorubicin-eluting beads;   Drug: mitomycin C;   Drug: sorafenib tosylate;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Refractory Cutaneous T-cell Lymphoma
Interventions:   Drug: bexarotene;   Drug: bexarotene
Sponsors:   Eisai Inc.;   Eisai Inc.
Recruiting - verified January 2012

Condition:   Multiple Myeloma
Intervention:   Drug: BT062
Sponsors:   Biotest Pharmaceuticals Corporation;   Biotest Pharmaceuticals Corporation;   Biotest
Recruiting - verified December 2011

Conditions:   Lymphoma;   Lymphoproliferative Disorder
Interventions:   Other: biologic sample preservation procedure;   Other: informational intervention
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Leukemia-Lymphoma, Adult T-Cell
Intervention:   Drug: Etoposide, Vincristine, Doxorubicin, Prednisone, Cyclophosphamide (EPOCH) with Bortezomib and Raltegravir
Sponsors:   Washington University School of Medicine;   Washington University School of Medicine
Recruiting - verified May 2012

Conditions:   ErbB2 Overexpressing;   Solid Tumors;   Metastatic Breast Cancer;   Neoplasms, Breast
Intervention:   Drug: lapatinib
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified December 2011

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: cisplatin;   Drug: paclitaxel;   Drug: veliparib
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Leukemia, Lymphocytic, Chronic, B-Cell;   Chronic Lymphocytic Leukemia;   Lymphoma, Small Lymphocytic
Intervention:   Drug: Lenalidomide, Rituximab, and Cyclophosphamide
Sponsors:   Emory University;   Emory University;   Celgene Corporation
Recruiting - verified November 2011

Condition:   Liver Cancer
Interventions:   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: vincristine sulfate;   Procedure: liver transplantation;   Procedure: therapeutic conventional surgery
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified November 2011

Condition:   Cervical Cancer
Interventions:   Drug: carboplatin;   Drug: cisplatin;   Drug: paclitaxel
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: cediranib maleate;   Drug: cilengitide;   Other: enzyme-linked immunosorbent assay;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Procedure: magnetic resonance imaging
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Non-Hodgkin's Lymphoma
Interventions:   Drug: YM155;   Biological: Rituximab
Sponsors:   Astellas Pharma Inc;   Astellas Pharma Inc
Recruiting - verified March 2012

Condition:   Endometrial Cancer
Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: ixabepilone;   Drug: paclitaxel;   Drug: temsirolimus
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified July 2011

Conditions:   Relapsed T-Cell Acute Lymphoblastic Leukemia;   Relapsed T-Cell Lymphoblastic Lymphoma
Interventions:   Drug: Nelarabine;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Methotrexate;   Drug: Filgrastim
Sponsors:   Therapeutic Advances in Childhood Leukemia Consortium;   Therapeutic Advances in Childhood Leukemia Consortium;   GlaxoSmithKline
Recruiting - verified November 2011

Conditions:   Adenocarcinoma;   Her2+;   Advanced Metastatic Breast Cancer;   Metastatic ErbB2;   Invasive Breast Cancer;   Advanced Breast Cancer;   Cancer;   ErbB2+
Interventions:   Drug: Lapatinib;   Biological: Trastuzumab
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified May 2012

Condition:   Head and Neck Cancer
Interventions:   Biological: cetuximab;   Radiation: intensity-modulated radiation therapy
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Ovarian Cancer;   Sarcoma
Interventions:   Drug: carboplatin;   Drug: ifosfamide;   Drug: paclitaxel
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Leukemia
Interventions:   Genetic: DNA analysis;   Genetic: RNA analysis;   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization;   Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified December 2011

Condition:   Venous Thromboembolism
Intervention:   Drug: Fragmin
Sponsors:   Eisai Inc.;   Eisai Inc.
Recruiting - verified April 2012

Condition:   Advanced Non-Small Cell Lung Cancer
Interventions:   Drug: Pemetrexed;   Drug: Carboplatin;   Drug: Paclitaxel;   Biological: Bevacizumab
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified May 2012

Condition:   Lung Cancer
Interventions:   Biological: bevacizumab;   Biological: cetuximab;   Drug: carboplatin;   Drug: paclitaxel
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Bladder Cancer;   Prostate Cancer;   Transitional Cell Cancer of the Renal Pelvis and Ureter;   Urethral Cancer
Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Drug: placebo administration
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified August 2011

Condition:   Endometrial Cancer
Interventions:   Drug: carboplatin;   Drug: cisplatin;   Drug: paclitaxel
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Breast Cancer
Interventions:   Drug: Exemestane;   Drug: Docetaxel, cytoxan
Sponsors:   Emory University;   Emory University;   Pfizer
Recruiting - verified February 2012

Conditions:   Brain and Central Nervous System Tumors;   Lymphoma;   Neuroblastoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Drug: crizotinib;   Other: pharmacogenomic studies;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2012

Conditions:   Renal Cell Carcinoma;   Non-hodgkin's Lymphoma
Intervention:   Biological: MDX-1203
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified February 2012

Condition:   Prostate Cancer
Interventions:   Drug: bicalutamide;   Drug: buserelin;   Drug: flutamide;   Drug: goserelin acetate;   Drug: leuprolide acetate;   Drug: triptorelin;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Myelodysplastic Syndromes
Interventions:   Drug: Deferasirox;   Drug: Deferasirox placebo
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified March 2012

Condition:   Colon Cancer With Metastases to the Liver
Interventions:   Device: LC bead loaded with Irinotecan;   Drug: FOLFOX6 and Avastin
Sponsors:   University of Louisville;   University of Louisville;   Biocompatibles UK Ltd
Recruiting - verified November 2011

Condition:   Multiple Myeloma
Intervention:   Drug: Vorinostat, Lenalidomide, Bortezomib, Dexamethasone
Sponsors:   Emory University;   Emory University;   Merck;   Celgene Corporation
Recruiting - verified April 2012

Condition:   Carcinoma, Non-Small-Cell Lung
Intervention:   Drug: PF-02341066
Sponsors:   Pfizer;   Pfizer
Recruiting - verified May 2012

Condition:   Carcinoma, Non-Small-Cell Lung
Interventions:   Drug: PF-02341066;   Drug: Pemetrexed;   Drug: Docetaxel
Sponsors:   Pfizer;   Pfizer
Recruiting - verified April 2012

Conditions:   Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   Acute Myeloid Leukemia
Interventions:   Drug: Panobinostat (LBH589) and 5-Azacytidine;   Drug: 5-Azacytidine
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified March 2012

Condition:   Relapsed and Refractory Multiple Myeloma
Intervention:   Drug: Oral MLN9708
Sponsors:   Millennium Pharmaceuticals, Inc.;   Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012

Conditions:   Pain, Burning;   Pain, Crushing;   Pain, Migratory;   Pain, Radiating;   Pain, Splitting
Interventions:   Drug: JNJ-42160443;   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   Janssen Research & Development, LLC
Recruiting - verified May 2012

Condition:   Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)
Interventions:   Drug: Vc-RCHOP;   Drug: RCHOP
Sponsors:   Millennium Pharmaceuticals, Inc.;   Millennium Pharmaceuticals, Inc.
Recruiting - verified January 2012

Condition:   Metastatic Breast Cancer
Interventions:   Drug: Dasatinib;   Drug: Ixabepilone
Sponsors:   Accelerated Community Oncology Research Network;   Accelerated Community Oncology Research Network;   Bristol-Myers Squibb
Recruiting - verified February 2012

Condition:   Brain and Central Nervous System Tumors
Intervention:   Other: biologic sample preservation procedure
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Chordoma;   Desmoid Tumor;   Sarcoma
Interventions:   Genetic: reverse transcriptase-polymerase chain reaction;   Other: biologic sample preservation procedure;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Breast Cancer
Interventions:   Drug: Trastuzumab (Herceptin);   Drug: Trastuzumab (Herceptin) plus Everolimus
Sponsors:   Emory University;   Emory University;   Genentech;   Novartis Pharmaceuticals
Recruiting - verified November 2011

Condition:   Non Small Cell Lung Cancer
Interventions:   Drug: Pemetrexed;   Drug: Carboplatin
Sponsors:   Sarah Cannon Research Institute;   Sarah Cannon Research Institute;   Eli Lilly and Company
Recruiting - verified March 2012

Condition:   Colon Cancer
Intervention:  
Sponsors:   Agendia;   Agendia
Recruiting - verified March 2012

Condition:   Neuroblastoma
Interventions:   Genetic: fluorescence in situ hybridization;   Genetic: gene expression analysis;   Genetic: nucleic acid amplification;   Genetic: polymerase chain reaction;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: cytology specimen collection procedure;   Other: flow cytometry;   Procedure: biopsy
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Kidney Cancer;   Nonneoplastic Condition
Interventions:   Genetic: loss of heterozygosity analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: immunohistochemistry staining method;   Procedure: computed tomography;   Procedure: magnetic resonance imaging
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Leukemia;   Neoplasm of Uncertain Malignant Potential;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention:   Other: cytology specimen collection procedure
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Intervention:   Other: diagnostic laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions:   Other: flow cytometry;   Other: immunohistochemistry staining method
Sponsors:   National Cancer Institute (NCI);   Southeastern Gynecologic Oncology, LLP - Northside
Recruiting - verified July 2009

Condition:   Cancer
Intervention:   Other: biologic sample preservation procedure
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified December 2011

Condition:   Sarcoma
Interventions:   Other: biologic sample preservation procedure;   Other: medical chart review
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Brain and Central Nervous System Tumors
Interventions:   Biological: anti-PDGFR alpha monoclonal antibody IMC-3G3;   Biological: ramucirumab
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI);   ImClone LLC
Recruiting - verified April 2012

Condition:   Sarcoma
Intervention:   Other: biologic sample preservation procedure
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Acute Lymphoblastic Leukemia
Interventions:   Behavioral: Physical Therapy;   Behavioral: Support
Sponsors:   St. Jude Children's Research Hospital;   St. Jude Children's Research Hospital;   National Cancer Institute (NCI)
Recruiting - verified December 2011

Conditions:   Leukemia;   Lymphoma
Intervention:   Other: biologic sample preservation procedure
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Leukemia;   Lymphoma
Intervention:   Other: biologic sample preservation procedure
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Lymphoma
Intervention:   Other: biologic sample preservation procedure
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Breast Cancer
Interventions:   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Sunitinib;   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Sunitinib
Sponsors:   Sarah Cannon Research Institute;   Sarah Cannon Research Institute;   Pfizer
Recruiting - verified March 2012

Condition:   Endometrial Cancer
Interventions:   Drug: Ixabepilone;   Drug: Doxorubicin;   Drug: Paclitaxel
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified February 2012

Condition:   Bone Metastases
Intervention:   Device: Bone Scan: F18-Fluoride PET/CT or TC-MDP
Sponsors:   American College of Radiology - Image Metrix;   American College of Radiology - Image Metrix;   Academy of Molecular Imaging
Recruiting - verified June 2011

Condition:   Neuroblastoma
Interventions:   Drug: Bevacizumab;   Drug: cyclophosphamide;   Drug: zoledronic acid
Sponsors:   New Approaches to Neuroblastoma Therapy Consortium;   New Approaches to Neuroblastoma Therapy Consortium;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Breast Cancer;   Lung Cancer;   Metastatic Cancer;   Multiple Myeloma and Plasma Cell Neoplasm;   Prostate Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention:   Procedure: assessment of therapy complications
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Breast Cancer
Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Prostate Cancer
Interventions:   Drug: Ipilimumab;   Drug: Placebo
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified December 2011

Condition:   Leukemia
Interventions:   Drug: arsenic trioxide;   Drug: cytarabine;   Drug: idarubicin;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: mitoxantrone hydrochloride;   Drug: tretinoin;   Genetic: cytogenetic analysis;   Genetic: polymerase chain reaction;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Non-Small Cell Lung Cancer;   Anemia;   Cancer;   Lung Cancer
Interventions:   Drug: darbepoetin alfa 500 mcg Q3W;   Drug: placebo
Sponsors:   Amgen;   Amgen
Recruiting - verified May 2012

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions:   Biological: immunological adjuvant OPT-821;   Biological: polyvalent antigen-KLH conjugate vaccine
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Small Cell Lung Cancer;   Extensive Stage;   Chemonaive
Intervention:   Drug: Bendamustine, Irinotecan, Etoposide/Carboplatin
Sponsors:   University of Alabama at Birmingham;   University of Alabama at Birmingham;   National Comprehensive Cancer Network
Recruiting - verified April 2012

Condition:   Breast Cancer
Interventions:   Biological: bevacizumab;   Biological: pegfilgrastim;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Pancreatic Neoplasms
Interventions:   Drug: LY2603618;   Drug: Gemcitabine
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified May 2012

Conditions:   Breast Neoplasms;   Breast Cancer;   Cancer of the Breast
Intervention:   Drug: Docetaxel and Cytoxan
Sponsors:   Emory University;   Emory University;   Sanofi-Aventis
Recruiting - verified February 2012

Condition:   Breast Cancer
Interventions:   Drug: trastuzumab emtansine;   Drug: lapatinib;   Drug: capecitabine [Xeloda]
Sponsors:   Genentech;   Genentech
Recruiting - verified April 2012

Conditions:   Multiple Myeloma;   Plasma Cell Leukemia
Interventions:   Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous;   Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous;   Drug: Dexamethasone, steroid; oral
Sponsors:   Array BioPharma;   Array BioPharma
Recruiting - verified February 2012

Condition:   Lymphoma
Interventions:   Biological: bleomycin sulfate;   Biological: filgrastim;   Drug: ABVD regimen;   Drug: BEACOPP regimen;   Drug: cyclophosphamide;   Drug: dacarbazine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: prednisone;   Drug: procarbazine hydrochloride;   Drug: vinblastine sulfate;   Drug: vincristine sulfate;   Radiation: fludeoxyglucose F 18
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Conditions:   Endometrial Cancer;   Fatigue;   Neurotoxicity
Interventions:   Drug: carboplatin;   Drug: paclitaxel;   Radiation: brachytherapy;   Radiation: intensity-modulated radiation therapy;   Radiation: radiation therapy
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Cervical Cancer
Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: paclitaxel;   Drug: topotecan hydrochloride
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified December 2011

Conditions:   Solid Tumors;   Neoplasms, Breast;   Cancer
Interventions:   Drug: Lapatinib in combination with an anti-cancer agent;   Drug: Lapatinib;   Drug: Lapatinib in combination with an anti-cancer agent as specified by parent protocol
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified February 2012

Conditions:   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer
Interventions:   Drug: capecitabine;   Drug: gemcitabine hydrochloride;   Procedure: adjuvant therapy;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Multiple Myeloma;   Plasma Cell Neoplasm
Interventions:   Drug: Lenalidomide & Dexamethasone;   Drug: Lenalidomide & Dexamethasone;   Drug: Lenalidomide & Dexamethasone
Sponsors:   PrECOG, LLC.;   PrECOG, LLC.;   Celgene Corporation
Recruiting - verified April 2012

Condition:   Diffuse Large B-cell Lymphoma
Interventions:   Drug: RAD001;   Drug: Placebo
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Condition:   Leukemia
Intervention:   Drug: Midostaurin
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Conditions:   Brain and Central Nervous System Tumors;   Chemotherapeutic Agent Toxicity;   Cognitive/Functional Effects;   Neurotoxicity;   Psychosocial Effects of Cancer and Its Treatment;   Radiation Toxicity;   Therapy-related Toxicity
Interventions:   Other: questionnaire administration;   Procedure: cognitive assessment;   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Leukemia
Interventions:   Drug: Dasatinib;   Drug: Dasatinib
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified February 2012

Condition:   Breast Cancer
Interventions:   Biological: trastuzumab;   Radiation: radiation therapy
Sponsors:   National Cancer Institute (NCI);   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   B-cell Chronic Lymphocytic Leukemia
Interventions:   Drug: Lenalidomide;   Drug: Placebo
Sponsors:   Celgene Corporation;   Celgene Corporation
Recruiting - verified May 2012

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: Pemetrexed;   Drug: Pemetrexed;   Drug: Paclitaxel;   Drug: Carboplatin;   Biological: Bevacizumab;   Biological: Bevacizumab
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified May 2012

Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Cancer
Interventions:   Biological: panitumumab;   Drug: cisplatin;   Drug: docetaxel;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery;   Radiation: radiation therapy
Sponsors:   National Cancer Institute (NCI);   American College of Surgeons;   National Cancer Institute (NCI)
Recruiting - verified June 2011

Condition:   Acute Myeloid Leukemia
Intervention:   Drug: 5-Azacitidine, Mylotarg
Sponsors:   University of California, San Diego;   University of California, San Diego;   Celgene Corporation;   Pfizer
Recruiting - verified February 2012

Condition:   Cancer, Multiple Indications
Interventions:   Biological: Anti-PDL-1 antibody;   Biological: Anti-PDL-1 antibody;   Biological: Anti-PDL-1 antibody;   Biological: Anti-PDL-1 antibody;   Biological: Anti-PDL-1 antibody
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified May 2012

Condition:   Breast Cancer
Interventions:   Drug: PD 0332991;   Drug: letrozole;   Drug: letrozole
Sponsors:   Pfizer;   Pfizer
Recruiting - verified April 2012

Condition:   Hematologic Malignancies, Multiple Myeloma, Lymphoma
Intervention:   Drug: MLN4924
Sponsors:   Millennium Pharmaceuticals, Inc.;   Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012

Condition:   Ovarian Neoplasms
Interventions:   Drug: AMG 479;   Drug: AMG 479 Placebo
Sponsors:   Cancer International Research Group;   Cancer International Research Group
Recruiting - verified March 2012

Condition:   Non Small Cell Lung Cancer
Interventions:   Drug: Pemetrexed;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Cisplatin;   Drug: Vinorelbine;   Drug: Paclitaxel;   Drug: Carboplatin;   Radiation: Thoracic Radiation Therapy (TRT);   Radiation: Thoracic Radiation Therapy (TRT)
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified May 2012

Condition:   Retinoblastoma
Interventions:   Genetic: DNA ploidy analysis;   Genetic: DNA stability analysis;   Genetic: Southern blotting;   Genetic: genetic linkage analysis;   Genetic: loss of heterozygosity analysis;   Genetic: mutation analysis;   Genetic: polymorphism analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: environmental carcinogenesis study;   Other: questionnaire administration;   Other: study of socioeconomic and demographic variables;   Procedure: evaluation of cancer risk factors;   Procedure: mutation carrier screening
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Glioblastoma
Intervention:   Drug: bsi-201 plus temozolomide
Sponsors:   Sanofi-Aventis;   Sanofi-Aventis;   BiPar Sciences
Recruiting - verified June 2011

Conditions:   Lung Neoplasm;   Carcinoma Non-small Cell Lung Cancer Stage IIIA;   Carcinoma Non-small Cell Lung Cancer Stage IIIB;   Carcinoma Non-small Cell Lung Cancer Stage IV
Interventions:   Biological: Lucanix™;   Other: Placebo Comparator
Sponsors:   NovaRx Corporation;   NovaRx Corporation
Recruiting - verified April 2012

Condition:   Advanced Nonhematologic Malignancies
Intervention:   Drug: MLN4924
Sponsors:   Millennium Pharmaceuticals, Inc.;   Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012

Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer;   Uterine Neoplasms;   Endometrial Cancer;   Vaginal Cancer;   Vulvar Cancer;   Cervical Cancer;   Lung Cancer;   Carcinoid Tumor of Lung;   Sarcoma of Lung;   Mesothelioma;   Colorectal Cancer
Intervention:  
Sponsors:   Precision Therapeutics;   Precision Therapeutics
Recruiting - verified June 2011

Condition:   Esophageal Cancer
Interventions:   Biological: cetuximab;   Drug: cisplatin;   Drug: paclitaxel;   Radiation: radiation therapy
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Brain and Central Nervous System Tumors
Interventions:   Biological: filgrastim;   Drug: carboplatin;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: etoposide phosphate;   Drug: methotrexate;   Drug: thiotepa;   Drug: vincristine sulfate;   Genetic: mutation analysis;   Other: immunohistochemistry staining method;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: 3-dimensional conformal radiation therapy
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Breast Cancer
Interventions:   Drug: letrozole;   Genetic: RNA analysis;   Genetic: gene expression analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Procedure: biopsy;   Procedure: therapeutic conventional surgery
Sponsors:   Vanderbilt-Ingram Cancer Center;   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   MDS;   AML;   Solid Tumors;   Multiple Myeloma;   Non-Hodgkin's Lymphoma;   Hodgkin's Disease
Interventions:   Drug: azacitidine;   Drug: azacitidine;   Drug: azacitidine;   Drug: azacitidine;   Drug: azacitidine;   Drug: azacitidine;   Drug: azacitidine
Sponsors:   Celgene Corporation;   Celgene Corporation
Recruiting - verified March 2012

Conditions:   Nervous System Neoplasms;   Brain Diseases;   Central Nervous System Diseases;   Neoplasm Metastasis;   Brain Neoplasms
Interventions:   Drug: ABT-888;   Radiation: Whole Brain Radiation Therapy
Sponsors:   Abbott;   Abbott
Recruiting - verified May 2012

Condition:   Multiple Myeloma and Plasma Cell Neoplasm
Interventions:   Drug: bortezomib;   Drug: dexamethasone;   Drug: lenalidomide
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified June 2011

Condition:   Lung Cancer
Interventions:   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group
Recruiting - verified May 2012

Conditions:   Lymphoma, B-Cell;   Follicular Lymphoma
Intervention:   Drug: rituximab, cyclophosphamide, doxorubicin, vincristine, bortezomib, prednisone
Sponsors:   Emory University;   Emory University;   Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2012

Condition:   Head and Neck Cancer
Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: cisplatin;   Drug: docetaxel;   Drug: fluorouracil
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: sapacitabine;   Drug: sapacitabine;   Drug: sapacitabine;   Drug: sapacitabine;   Drug: sapacitabine;   Drug: sapacitabine;   Drug: sapacitabine;   Drug: Sapacitabine;   Drug: sapacitabine
Sponsors:   Cyclacel Pharmaceuticals, Inc.;   Cyclacel Pharmaceuticals, Inc.
Recruiting - verified November 2011

Condition:   Prostate Cancer
Interventions:   Drug: bicalutamide;   Drug: flutamide;   Radiation: radiation therapy
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI);   Cancer and Leukemia Group B
Recruiting - verified May 2012

Condition:   Neuroendocrine Carcinoma
Interventions:   Biological: bevacizumab;   Biological: recombinant interferon alfa-2b;   Drug: octreotide acetate
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Condition:   Prostate Cancer
Intervention:   Drug: [18F]FACBC
Sponsors:   Emory University;   David M. Schuster, MD
Recruiting - verified December 2011

Condition:   Leukemia
Interventions:   Drug: asparaginase;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: etoposide;   Drug: lestaurtinib;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: pegaspargase;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Prostate Cancer
Interventions:   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy;   Radiation: samarium Sm 153 lexidronam pentasodium
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Retinoblastoma
Interventions:   Biological: filgrastim;   Drug: carboplatin;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: thiotepa;   Drug: vincristine sulfate;   Procedure: autologous bone marrow transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   NHL;   Lymphoma, Non-Hodgkin;   Lymphoma, B-Cell;   Lymphoma, Follicular;   Lymphoma, Intermediate-Grade;   Lymphoma, Large-Cell;   Lymphoma, Low-Grade;   Lymphoma, Mixed-Cell;   Lymphoma, Small-Cell;   Leukemia, Lymphocytic, Chronic;   Leukemia, B-Cell, Chronic;   Leukemia, Prolymphocytic;   Leukemia, Small Lymphocytic;   Lymphoma, Small Lymphocytic;   Lymphoma, Lymphoplasmacytoid, CLL;   Lymphoplasmacytoid Lymphoma, CLL;   CLL;   SLL
Intervention:   Biological: veltuzumab
Sponsors:   Immunomedics, Inc.;   Immunomedics, Inc.
Recruiting - verified March 2012

Condition:   Brain Tumors
Intervention:   Drug: temozolomide, thiotepa, carboplatin, 13-cis-retinoic acid
Sponsors:   New York University School of Medicine;   New York University School of Medicine;   Children's Hospitals and Clinics of Minnesota;   Schneider Children's Hospital
Recruiting - verified January 2012

Conditions:   Gastroesophageal Junction Adenocarcinoma;   Gastric Cancer
Interventions:   Drug: Docetaxel, Leucovorin, Fluorouracil, Cisplatin;   Drug: Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Sanofi-Aventis;   Roche/Genetech;   City of Hope National Medical Center;   Piedmont Hospital Research Institute (PHRI);   Medical College of Wisconsin;   Queens Health Network;   Weill Medical College of Cornell University;   Memorial Cancer Institute, Florida;   University of Pittsburgh;   Long Island Jewish Medical Center;   Nebraska Cancer Specialists Methodist Estabrook Cancer Center
Recruiting - verified January 2012

Condition:   Lung Cancer
Interventions:   Procedure: therapeutic thoracoscopy;   Procedure: videothoracoscopy
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   American College of Surgeons;   Southwest Oncology Group
Recruiting - verified April 2012

Condition:   Endometrial Cancer
Interventions:   Drug: cisplatin;   Radiation: brachytherapy;   Radiation: external beam radiation therapy
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Lung Cancer
Interventions:   Drug: carboplatin;   Drug: cisplatin;   Drug: etoposide;   Drug: sunitinib malate
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified November 2011

Conditions:   Anovulation;   FHA;   Eumenorrhea;   Polycystic Ovary Syndrome
Interventions:   Procedure: Screening evaluation;   Procedure: Meal Response;   Genetic: Blood Collection;   Procedure: Functional MRI;   Procedure: Endocrine Assessment
Sponsors:   Emory University;   Emory University
Not yet recruiting - verified May 2011

Conditions:   Multiple Sclerosis;   Transverse Myelitis;   Neuromyelitis Optica;   Acute Disseminated Encephalomyelitis;   Optic Neuritis
Intervention:  
Sponsors:   Accelerated Cure Project for Multiple Sclerosis;   Accelerated Cure Project for Multiple Sclerosis
Recruiting - verified March 2012

Conditions:   Metastatic Breast Cancer;   Advanced Breast Cancer;   Gastrointestinal Stromal Tumor;   Hepatocellular Carcinoma;   Metastasizing Breast Cancer (F);   Metastatic Castration-Resistant Prostrate Cancer;   Metastatic Renal Cell Cancer;   Non Small Cell Lung Cancer;   Pancreatic Islet Cell Carcinoma
Intervention:   Drug: sunitinib
Sponsors:   Pfizer;   Pfizer
Recruiting - verified May 2012

Conditions:   Leukemia;   Lymphoma
Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: nelarabine;   Drug: pegaspargase;   Drug: prednisone;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Oral Cancer
Interventions:   Drug: Erlotinib;   Drug: Placebo
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Lung Cancer
Intervention:   Drug: RAD001
Sponsors:   Emory University;   Emory University
Recruiting - verified May 2012

Condition:   Brain and Central Nervous System Tumors
Interventions:   Biological: filgrastim;   Drug: carboplatin;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: isotretinoin;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Kidney Cancer;   Metastatic Cancer
Interventions:   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: vincristine sulfate;   Procedure: therapeutic conventional surgery;   Radiation: radiation therapy
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Condition:   Leukemia
Interventions:   Biological: filgrastim;   Drug: asparaginase;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: etoposide phosphate;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   Breast Cancer;   Cognitive/Functional Effects;   Lung Cancer;   Metastatic Cancer;   Prostate Cancer
Interventions:   Radiation: radiation therapy;   Radiation: stereotactic radiosurgery
Sponsors:   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   National Cancer Institute (NCI);   American College of Surgeons;   Eastern Cooperative Oncology Group;   Radiation Therapy Oncology Group
Recruiting - verified July 2011

Condition:   Kidney Neoplasms
Interventions:   Drug: Sunitinib malate;   Other: Placebo
Sponsors:   Pfizer;   Pfizer
Recruiting - verified May 2012

Condition:   Lymphoma
Interventions:   Drug: rituximab;   Drug: bortezomib;   Drug: Ibritumomab tiuxetan
Sponsors:   Northwestern University;   Northwestern University;   Robert H. Lurie Cancer Center
Recruiting - verified October 2011

Condition:   Neoplasms, Breast
Intervention:   Drug: lapatinib + capecitabine
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified April 2012

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: carboplatin;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: thiotepa;   Drug: vincristine sulfate
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified August 2011

Condition:   Lung Cancer
Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: docetaxel;   Drug: gemcitabine hydrochloride;   Drug: pemetrexed disodium;   Drug: vinorelbine tartrate
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Southwest Oncology Group;   Cancer and Leukemia Group B;   NCIC Clinical Trials Group;   North Central Cancer Treatment Group
Recruiting - verified February 2012

Condition:   Breast Cancer
Intervention:   Drug: Zometa® (zoledronic acid)
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Condition:   Prostate Cancer
Interventions:   Drug: antiandrogen therapy;   Drug: docetaxel
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Breast Cancer
Interventions:   Drug: anastrozole;   Drug: chemotherapy;   Drug: exemestane;   Drug: letrozole;   Drug: tamoxifen citrate
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Southwest Oncology Group;   Cancer and Leukemia Group B;   American College of Surgeons;   North Central Cancer Treatment Group;   NCIC Clinical Trials Group;   National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified July 2011

Condition:   Precancerous Conditions
Intervention:   Drug: Erlotinib & Celecoxib
Sponsors:   Emory University;   Emory University;   National Institutes of Health (NIH)
Recruiting - verified January 2012

Condition:   Hematologic Malignancies
Intervention:   Drug: Granulocyte Colony Stimulating Factor
Sponsors:   Emory University;   Emory University
Recruiting - verified November 2011

Condition:   Prostate Cancer
Interventions:   Drug: Docetaxel;   Drug: Prednisone
Sponsors:   Department of Veterans Affairs;   Department of Veterans Affairs;   Sanofi-Aventis
Recruiting - verified September 2011

Condition:   Sarcoma
Interventions:   Biological: PEG-interferon alfa-2b;   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: methotrexate
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI);   University College London Hospitals
Recruiting - verified June 2011

Condition:   Breast Cancer
Interventions:   Radiation: 3-dimensional conformal accelerated partial breast irradiation;   Radiation: brachytherapy;   Radiation: whole breast irradiation
Sponsors:   National Cancer Institute (NCI);   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   Southwest Oncology Group
Recruiting - verified May 2012

Condition:   Lymphoma
Interventions:   Biological: rituximab;   Drug: cisplatin;   Drug: cytarabine;   Drug: dexamethasone;   Drug: gemcitabine hydrochloride;   Other: clinical observation
Sponsors:   NCIC Clinical Trials Group;   NCIC Clinical Trials Group
Recruiting - verified May 2012

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: lomustine;   Drug: vincristine sulfate
Sponsors:   National Cancer Institute (NCI);   Children's Hospital of Philadelphia
Recruiting - verified June 2009

Condition:   Neuroblastoma
Interventions:   Biological: aldesleukin;   Biological: monoclonal antibody Ch14.18;   Biological: sargramostim;   Drug: isotretinoin
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Sarcoma
Interventions:   Biological: dactinomycin;   Drug: busulfan;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: melphalan;   Drug: vincristine sulfate;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   National Cancer Institute (NCI);   University Hospitals, Leicester;   National Cancer Institute (NCI);   Children's Cancer and Leukaemia Group;   Societe Francaise Oncologie Pediatrique;   European Organization for Research and Treatment of Cancer - EORTC;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria;   Swiss Group for Clinical Cancer Research;   EBMT Solid Tumors Working Party;   Children's Oncology Group
Recruiting - verified December 2011

Condition:   Ovarian Cancer
Intervention:   Drug: paclitaxel
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012